 
CLINICAL STUDY PROTOCOL 
IND Number 115459 
 
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 
Parallel-Group, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy 
of GR-MD-02 for the Treatment of Li ver Fibrosis and Resultant Portal 
Hypertension in Patie nts with NASH Cirrhosis 
The NASH-CX Trial 
 
1
GT-026 
Sponsor: Galectin Therapeutics Inc 
[ADDRESS_20548]: Peter G. Traber, MD 
President, CEO, CMO 
Telephone: [PHONE_341] 
[COMPANY_003] Project Manager: Vivian Sadler 
Associate Director, Global Project Management 
General Medicine [ADDRESS_20549] 
Wilmington, NC [ZIP_CODE] 
[COMPANY_003] Medical Monitor: Michael Barri, MD  
[ADDRESS_20550] 
Wilmington, NC [ZIP_CODE] 
SAE Hotline: [PHONE_342] 
Version of Protocol: GT-026 Original 
Date of Protocol:  20 February 2015 
 
 
 
CONFIDENTIAL 
All financial and nonfinancial support for this study will be provided by [CONTACT_21696]. The concepts and informa tion contained in this document or generated 
during the study are considered pr oprietary and may not be disc losed in whole or in part 
without the expressed, wr itten consent of Galec tin Therapeutics Inc. 
The study will be conducted according to th e International Conference on Harmonisation 
harmonised tripartite guideline E6(R1): Good Clinical Practice. 
 
2
3
4
5
6
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20551] Selection and W ithdrawal Criteria ...................................................................... 34  
4.1 Selection of Study Population ................................................................................. 34  
4.1.1  Inclusion Criteria ..................................................................................... 34  
4.1.2  Exclusion Criteria .................................................................................... 35  
4.2 Withdrawal of Subjects from the Study .................................................................. 39  
4.2.1  Reasons for Withdrawal/Discontinuation ................................................ [ADDRESS_20552] ........................................................ 42  
5.4 Management of Clinical Supplies ........................................................................... 43  
7
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20553] Article Accountability ...................................................................... 43  
5.4.3  Other Supplies ......................................................................................... 44  
5.5 Overdose Management ........................................................................................... 44  
5.5.1  Treatment of Overdose ............................................................................ 44  
5.5.2  Medication Errors .................................................................................... 44  
5.5.3  Treatment of Medication Errors ............................................................... 45  
5.6 Misuse for Illegal Purposes ..................................................................................... 45  
5.7 Blinding .................................................................................................................. 45  
5.7.1  Breaking the Blind ................................................................................... 45  
5.8 Treatment Compliance ............................................................................................ 46  
5.9 Prior and Concomitant Therapy .............................................................................. 46  
5.10  Prohibited Medications or Therapi[INVESTIGATOR_014] ...................................................................... 46  
6 Study Assessments and Procedures .................................................................................. 48  
6.1 Study Visits ............................................................................................................. 48  
6.1.1  Prescreening Visit (Week –9) ................................................................... 48  
6.1.2  Screening Visit (Week -8 to Day 0) ......................................................... 49  
6.1.3  Treatment Phase ....................................................................................... 51  
[IP_ADDRESS]  Randomization ......................................................................................... 51  
[IP_ADDRESS]  Two Weeks Prior to Infusion Visit 1 ........................................................ 51  
[IP_ADDRESS]  Infusion Visit 1 (Week 1) ......................................................................... 51  
[IP_ADDRESS]  Infusion Visits 2, 3, 4, 5, and 6 (Weeks 3, 5, 7, 9, and 11 ± 3 Days, 
respectively) ............................................................................................. 52  
[IP_ADDRESS]  Infusion Visit 7 (Week 13 ± 3 Days) ....................................................... 53  
[IP_ADDRESS]  Infusion Visits 8, 9, 10, 11, and 12 (Weeks 15, 17, 19, 21, and 23 ± 3 Days) .................................................................................................. 54
 
[IP_ADDRESS]  Infusion Visit 13 (Week 25 ± 3 Days) ..................................................... 54  
[IP_ADDRESS]  Infusion Visits 14, 15, 16, 17, 18, and 19 (Weeks 27, 29, 31, 33, 35, and 37 ± 3 Days) ............................................................................................. 56
 
[IP_ADDRESS]  Infusion Visit 20 (Week 39 ± 3 Days) ..................................................... 56  
[IP_ADDRESS]  Infusion Visit 21 (Week 41 ± 3 Days) ..................................................... 57  
[IP_ADDRESS]  Infusion Visits 22, 23, 24, and 25 (Weeks 43, 45, 47, and 49 ± 3 Days) . 58  
[IP_ADDRESS]  Infusion Visit 26 (Week 51 ± 3 Days) ..................................................... 58  
6.1.4  Follow-up (14-28 Days After Final Dose; Weeks 53-55 ± 3 Days) ........ 59  
8
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 8 6.1.5  Follow-up/Early Termination (Week 57 ± 3 Days) ................................. 60  
[IP_ADDRESS]  Open-Label Safety Extension Study ........................................................ [ADDRESS_20554] ...................................................................... 62  
6.2.5  Child-Turcotte-Pugh Score ...................................................................... 64  
6.2.6  MELD Score ............................................................................................ 65  
6.2.7  EGD Evaluation ....................................................................................... 65  
6.3 Exploratory Assessments ........................................................................................ 66  
6.3.1  Chronic Liver Disease Questionnaire ...................................................... 66  
6.3.2  Biomarkers ............................................................................................... 66  
[IP_ADDRESS]  Enhanced Liver Fibrosis Test ................................................................... 66  
[IP_ADDRESS]  FibroTest/FibroSure ................................................................................. 66  
[IP_ADDRESS]  Galectin-[ADDRESS_20555] Radiograph ..................................................................................... 68  
6.4.5  Adverse Events ........................................................................................ 68  
[IP_ADDRESS]  Definitions of Adverse Events ................................................................. 68  
[IP_ADDRESS]  Eliciting and Documenti ng Adverse Events ............................................ 69  
[IP_ADDRESS]  Reporting Adverse Events ....................................................................... 69  
[IP_ADDRESS]  Assessment of Severity ............................................................................ 70  
[IP_ADDRESS]  Assessment of Causality .......................................................................... 70  
[IP_ADDRESS]  Exceptions ................................................................................................ 71  
[IP_ADDRESS]  Follow-Up of Subjects Reporting Adverse Events .................................. 71  
6.4.6  Pregnancy ................................................................................................ 72  
6.4.7  Laboratory Analyses ................................................................................ 72  
6.4.8  Hematology .............................................................................................. 73  
6.4.9  Blood Chemistry ...................................................................................... 73  
9
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20556] Information and Consent ........................................................................... 88  
9 Investigator’s Obligations ................................................................................................ 90  
9.1 Confidentiality ........................................................................................................ 90  
9.2 Financial Disclosure and Obligations ..................................................................... 90  
9.3 Investigator Documentation .................................................................................... 91  
10
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20557] ......................................................................................................... 91  
9.5 Adherence to Protocol ............................................................................................ 91  
9.6 Adverse Events and Study Report Requirements ................................................... 92  
9.7 Investigator’s Final Report ..................................................................................... [ADDRESS_20558]................................................................................................................. .. 97  
12 Appendices .................................................................................................................... . 100  
12.1  Appendix: Schedule of Events .............................................................................. 100  
12.2  Appendix: The AUDIT Questionnaire .................................................................. 108  
12.3  Appendix: The Chronic Liver Disease Questionnaire .......................................... [ADDRESS_20559] of Tables 
Table 5-1  Composition of GR-MD-02 Concentrate ........................................................ 41  
Table 6-1  Child-Turcotte-Pugh Scoring System ............................................................. 64  
11
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 11 Table 6-2  Child-Turcotte-Pugh Classification ................................................................ 64  
Table 7-1  HVPG (mm Hg) at Baseline and 12 Mont hs for Subjects in the Placebo Group  
in the Timolol Clinical Study .......................................................................... 79  
Table 7-2  Absolute Change in HVPG (mm Hg) at 12 Months for Subjects in the Placebo  
Group in the Timolol Clinical Study ............................................................... 79  
Table 12-1  Schedule of Events - Prescreening and Screening ........................................ 101  
Table 12-2  Schedule of Events - Randomization, Treatment Phase, and Follow-up/Early 
Termination ................................................................................................... [ADDRESS_20560] of Figures 
Figure 3-1  Study Design GT-026 ...................................................................................... 29  
Figure 3-2  Prescreening and Screening Flow Chart GT-026 ............................................ 30  
12
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 12 Protocol Synopsis 
Protocol Number: GT-026 
Title: A Multicenter, Randomized, Placebo-Controlled, 
Double-Blind, Parallel-Group, Ph ase 2 Clinical Trial to 
Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients with NASH Cirrhosis. The 
NASH-CX Trial 
Sponsor: Galectin Therapeutics Inc 
[ADDRESS_20561] 
Norcross, GA [ZIP_CODE] 
Study Phase: Phase 2 
Study Centers: Approximately 45 to 60 study centers in the [LOCATION_002] and Canada 
Indication: Portal hypertension with cirrh osis or advanced bridging 
fibrosis due to nonalcoholic steatohepatitis (NASH) 
Rationale: Nonalcoholic steatohepatitis is a chronic inflammatory 
disease of the liver characterized  by [CONTACT_21697] a subset of subjects; the 
complications of portal hypertensi on due to liver fibrosis can 
result in death or liver transp lantation. There are currently no 
medical therapi[INVESTIGATOR_21671], and this th erapeutic area 
represents an area of significant unmet medical need. Galectin-3, a protein that bi nds to galactose-containing 
oligosaccharides, has been s hown to be critical in the 
pathophysiology of NASH and liver fibrosis. GR-MD-[ADDRESS_20562] udies. Therefore, the overall 
objective of this clin ical study is to establish the safety and 
efficacy of GR-MD-02 as compared to placebo in the reduction of portal pressure as a surrogate for a reduction in 
fibrosis in subjects with comp ensated cirrhosis due to NASH. 
13
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 13 Objectives: The primary objective is to evaluate the efficacy of 
GR-MD-02 on reducing hepatic ve nous pressure gradient 
(HVPG) as a measure of portal pressure compared to placebo 
at 1 year of treatment.  
Secondary objectives  are to evaluate differences in relevant 
assessments of fibrosis and cirrhosis between 
GR-MD-02-treated and placeb o-treated subjects. The 
secondary objectives are to evaluate:  
• The effect of GR-MD-02 on change in the collagen 
proportional area at 1 year compared to placebo as 
determined by [CONTACT_21698]  
• The effect of GR-MD-02 on liver stiffness as determined 
by [CONTACT_21699]® score prior to the first infusion, at 
Infusion Visit 13, and 14-28 days after final infusion as compared to placebo 
• The effect of GR-MD-[ADDRESS_20563]
30 (percentage dose 
recovery) value of the 13C-methacetin breath test (MBT) 
(for those study centers where the MBT is available) at 
screening, at Infusion Visit 13, and 14-28 days after final infusion as compared to placebo 
• The effect of GR-MD-02 on progression of cirrhosis at 
1 year as compared to placebo, defined as the development of any of the following:  
o esophageal variceal hemorrhage or portal 
hypertensive gastropathy hemorrhage (confirmed by 
[CONTACT_21700]) 
o clinically apparent ascites  
o spontaneous bacterial peritonitis 
o overt hepatic encephalopathy (defined by [CONTACT_21701], but 
should include the presence of lethargy, 
disorientation, inappropriate behavior, and the 
presence of asterixis) 
o an increase in Child-Turcotte-Pugh score ≥[ADDRESS_20564] without prior 
varices  
o progression from small to medium or large varices  
 
14
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 14  o reaching model for end-stage liver disease score ≥15 
as measured on 2 consecutive occasions  
o listing for a liver transplant  or the performance of a 
liver transplant 
o liver-related mortality 
 Exploratory objectives  are to evaluate: 
• Differences in health-related quality of life using the 
subject-completed chronic li ver disease questionnaire 
following administration of GR-MD-02 or placebo at 
1 year.  
• Baseline-adjusted change in FibroTest® (FibroSure®) and 
enhanced liver fibrosis scor e at Infusion Visits 7, 13, 20, 
and 14-28 days after final infusion 
• Changes in liver biopsy stai ning for alpha smooth muscle 
actin and galectin-3 in su bjects treated with GR-MD-02 
or placebo at 1 year 
Safety objectives  are to assess the safety and tolerability of 
GR-MD-02 versus placebo at 1 year. 
Pharmacokinetic Objectives are to: 
• Evaluate systemic exposure following multiple doses of 
GR-MD-02 in subjects with portal hypertension due to 
NASH cirrhosis. 
• Explore the population phar macokinetics of GR-MD-02 
in subjects with NASH w ith portal hypertension and 
cirrhosis or advanced bridging fibrosis. 
15
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20565] Population: Subjects will be entered into the study and randomly assigned 
if they have both an HVPG measurement greater than or 
equal to 6 mm Hg and a liver biopsy with advanced bridging fibrosis (Ishak stage 4) or
 cirrhosis (Ishak stage 5 or 6), 
presumably due to NASH. A liver biopsy diagnosis of cirrhosis or advanced bridging fibrosis, presumably due to 
NASH will include the following 2 categories: 1) cirrhosis or 
advanced bridging fibrosis with a definitive pathological 
diagnosis of NASH (presence of fat, ballooning degeneration, 
and inflammation) or 2) cirrh osis or advanced bridging 
fibrosis wherein the subject has greater than 5 years of 
obesity and/or diabetes with negative viral hepatitis markers 
and a biopsy showing cirrhosis with any amount of fat. 
Additional inclusion criteria will include age at least [ADDRESS_20566] history of 
significant alcohol consumption defined as more than 
20 grams per day in females and more than 30 grams per day in males for a period of more  than 3 consecutive months 
within 1 year prior to screen ing, history of recent weight 
reduction surgery, presence of a transjugular intrahepatic 
porto-systemic shunt, history of hepatic decompensation, evidence of other forms of liver  disease, laboratory values 
indicative of advanced cirrhosis (Child-Turcotte-Pugh Class B or C or model for end-st age liver disease greater than 
or equal to 15), various concomitant illnesses (human immunodeficiency virus-positive subjects, recent major surgery [within 8 weeks of randomization], uncontrolled 
heart disease, concurrent infection or fever of unknown origin, illicit drug use, histor y of malignancy), participation 
in an investigational new drug study within 30 days prior to 
randomization (including follo w-up visits) or at any time 
during the current study, clinic ally significant medical or 
psychiatric condition considered a high risk for participation 
in a study, failure to give informed consent, and known allergies to the investigati onal medicinal product (IMP) or 
any of its excipi[INVESTIGATOR_840]. 
16
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 16 Study Design: Study GT-026 is a Phase 2, multicenter, parallel-group, North 
American, randomized, placebo-controlled, double-blind study. This study will enroll subj ects with portal hypertension 
(HVPG greater than or equal to  6 mm Hg) who also have a 
liver biopsy showing advanced fi brosis (Ishak stage 4) or 
cirrhosis (Ishak stage 5 or 6) , presumably due to NASH, 
excluding subjects with medium and large varices and those 
with decompensated cirrhosis. All subjects are required to 
have signed institutional review  board- or independent ethics 
committee-approved informed consent form prior to 
undergoing any study speci fic procedures.  
 Subjects with portal hypertens ion and advanced bridging 
fibrosis or cirrhosis will be randomly assigned (1:1:1) to 
receive 1 of 3 treatment a ssignments including placebo, 
GR-MD-02 in a dose of 2 mg/kg lean body mass, or GR-MD-02 in a dose of 8 mg/kg lean body mass administered every other week over a 52-week period for a total of 26 intravenous infusions. The primary endpoint analysis is the baseline-adjus ted change in HVPG at 1 year 
(53-55 weeks) in subjects trea ted with placebo as compared 
to subjects treated with GR-MD-02 (2 mg/kg/week or 
8 mg/kg/week). 
 An esophagogastroduodenoscopy (EGD) with evaluation for varices, HVPG, and liver biopsy will be performed before the 
first infusion and after the final 26th dose of IMP. 
Additionally, prior to the first infusion, at Infusion Visit 13, 
and 14 to 28 days following final 26th infusion, subjects will undergo a FibroScan, an
 MBT (if available), and blood will 
be collected for assessment of biomarkers. 
All subjects are to attend 2 pos tdose visits: the first will occur 
[ADDRESS_20567] postdose visit. 
Subjects will be offered enrollment into a subsequent 
separate study, an open-label extension study, if there is adequate tolerability and no safety  issues or signs of clinical 
progression that would r ecommend discontinuation. 
Subjects who do not enroll in th e open-label extension study 
will be contact[CONTACT_21702] 6 months for 2 years 
and annually thereafter for a total of 4 years. 
17
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 17 Estimated Study 
Duration: Subjects will remain on study th erapy for a total of [ADDRESS_20568] a 1-week prescreening period, up to an 8-week screening period, and up to a 6-week postdosing period 
(2 postdose visits) for a total duration of up to 67 weeks. 
Efficacy Assessments: Efficacy assessments will include HVPG measurement, liver 
biopsy, EGD evaluation, Fibr oScan, a MBT (if available), 
progression of cirrhosis, chroni c liver disease questionnaire, 
and serum biomarker tests. 
Pharmacokinetic or 
Pharmacodynamic 
Assessments: Plasma levels of GR-MD-02 will be assessed in all subjects. 
Systemic drug exposure will be assessed at Infusion Visits 1, 2, 3, 4, 7, 10, 13, and 26 during the study. Population pharmacokinetics of GR-MD-02 in  subjects with NASH with 
portal hypertension and cirrhos is or advanced bridging 
fibrosis will be evaluated. 
Safety Assessments: Safety assessments will include incidence of adverse events 
(AEs) during study treatment, em ergent physical examination 
abnormalities, emergent vital sign measurements and 
electrocardiogram abnormalities, and laboratory parameter 
abnormalities. 
A data safety monitoring board (DSMB) will be established 
that includes a panel of at least [ADDRESS_20569] 1 infusion of study 
treatment will be evaluated for safety. The safety analyses 
will include evaluation of the incidence of treatment-emergent AEs (TEAEs), grade 3 or greater AEs, serious AEs (SAEs), and TEAEs leading to discontinuation of study treatment using the Common Terminology Criteria 
for Adverse Events Version 4.0 or higher. 
18
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 18 Study Drug, Dosage, 
and Route of 
Administration: Subjects in the GR-MD-02 treatment groups will be 
randomly assigned to receiv e either 2 mg/kg lean body 
weight (up to a maximum of 200 mg total) or 8 mg/kg lean 
body weight (up to a maximum of 800 mg total). The IMP 
will be diluted in 100 mL of normal saline and infused intravenously via a peripheral vein over a period of approximately 60 minutes. The IMP will be administered 
every other week for 52 weeks for a total of 26 doses. No 
dose modification for GR-MD-02 is allowed. Subjects in the placebo arm will receive placebo diluted in normal saline administered in the same fashion. Active drug and placebo will be blinded (by [CONTACT_21703]) by [CONTACT_21704]-colored intravenous bag covers and amber-colored 
tubing and sealed with tamper-evident tape. 
Sample Size: A total of 52 subjects will be randomly assigned into each of 
3 parallel treatment groups in a 1:1:1 ratio for a total of 
156 subjects in the study. 
19
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 19 Statistical Methods: All efficacy and safety parameters, subject demographics as 
well as medical and social history, and other baseline subject characteristics (including prior NASH treatments and associated response/side eff ects) will be summarized by 
[CONTACT_21705] 3 indi vidual treatment groups, for 
both GR-MD-02 treatment groups combined versus the placebo group, for the full-analysis  (intent-to-treat), modified 
intent-to-treat, and per-protocol sets. 
Baseline is defined as the last assessment prior to infusion 
with IMP (ie, the predosi ng assessment present in the 
database that is most proximate to the time of IMP 
administration). Measurements that are obtained after the first dose of study treatment will  be considered postbaseline 
values. Change from baseline is defined as the postbaseline 
value minus the baseline value. 
The primary efficacy endpoint analysis will be carried out 
using an analysis of covariance model, with the HVPG change from baseline at Weeks 53 to 55 as the dependent variable. The model will include treatment group at 
randomization and the baseline  HVPG as a covariate.  
Methods for dealing with mi ssing data including dates, 
efficacy and safety results will be  specified in the statistical 
analysis plan. 
Adverse events will be classified using the Medical 
Dictionary for Regulatory Activities (MedDRA) 
(Version 17.1), and summarized by [CONTACT_14340]. Events from the time of the subject signing informed consent must be reported. Adverse events prior to exposure to IMP are considered pretreatment AEs 
and will be provided in a listing separate from the listing for 
TEAEs.  
 Only TEAEs, and not pretreatment AEs, will be used for 
tabular summaries and be graded according to the protocol 
guidelines. Each AE will be assessed for relatedness to the IMP agent per se and for the rest of the infusion procedure. The duration of all TEAEs in days, from start to end, will be 
summarized as a numeric variable.  
20
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20570]’s 
participation in the study will be collected in the electronic 
case report form. Concomitant medications are defined as medications taken any time after the start of exposure to IMP. 
Prior medications are defined as nonstudy medications discontinued prior to the start of exposure to IMP. All other 
concomitant medications taken from [ADDRESS_20571]’s time on study will be collected in the electronic case report form. Concomitant medications are defined as medications taken any time after the star t of exposure to IMP. Prior 
medications are defined as medi cations discontinued prior to 
the start of exposure to IMP. The prior and concomitant medications taken during the study will be summarized using number of subjects (n) and percentage (%) by [CONTACT_21706], for both GR-MD-02 groups combined, for the placebo group, and overall (all subjects). All prior and 
concomitant medications will be coded using the WHO Drug Dictionary (Version 1 Sep 2014)  and further coded against 
Anatomic Therapeutic Chemical classification.  
Laboratory and vital sign meas urement will be evaluated 
over time using descriptive st atistics. Shift analyses of 
relevant clinical laboratory parameters will be produced 
showing shifts from baseline across low, normal, and high 
categories presented by [CONTACT_7206]. 
Date of Protocol: 20 February 2015 
21
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20572] 
ECG electrocardiogram 
eCRF electronic case report form 
EGD esophagogastroduodenoscopy 
ELF enhanced liver fibrosis 
FAS full-analysis set 
FDA US Food and Drug Administration 
GCP Good Clinical Practice 
GR-MD-02 galactoarabino-rhamnogalacturnate  
HIV human immunodeficiency virus 
HVPG hepatic venous pressure gradient 
ICF informed consent form 
ICH E6(R1) International Conference on Harmonisation harmonised tripartite 
guideline 
IEC independent ethics committee 
IMP investigational medicinal product 
INR international normalized ratio 
IRB institutional review board 
IV intravenous 
IWRS interactive we b response system 
kPa kiloPascals 
22
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20573] percentage dose recovery rate 
SAE serious adverse event 
SAP statistical analysis plan 
TBW total body weight 
TEAE treatment-emergent adverse event 
TLFB timeline followback 
Tn time point 
23
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 23 1 Introduction 
Nonalcoholic fatty liver disease (NAFLD), or  fatty liver, and nonalc oholic steatohepatitis 
(NASH) are common liver disorders in the United  States. The major feature in NAFLD is fat 
accumulation in hepatocytes with minimal infla mmation. It is estimated that the worldwide 
prevalence of NAFLD ranges from 6.3% to 33% with a median of 20% in the general 
population ( Chalasani  2012), but a recent study in asymptomatic middle-aged adults in the 
US suggests that it may be as high as 46% ( Williams 2011). A subset of individuals with 
NAFLD are found to have NASH, which is ch aracterized by [CONTACT_21707] (steatosis) with the addition of in flammatory cell infiltrates, evidence of damage 
to hepatocytes (ballooning degene ration), and the deposi tion of fibrous tissue.  It is estimated 
that 3% to 5% of Americans are affected by [CONTACT_21708] ( Chalasani  2005), with as many as 12.2% 
in asymptomatic adults ( Williams 2011). While the prevalence of cirrhosis in NASH is not 
clearly defined, as many as one-third of NASH subjects progr ess to advanced fibrosis 
(Caldwell  2010). The only therapy available to these advanced subjects is liver 
transplantation. Currently the pe rcentage of liver transplantations performed in the US for 
NASH is between 10% and 15%, but the numbers  are increasing and it has been suggested 
that it may become the leading cause for liv er transplantation over the next 20 years 
(Rinella 2011).  
The galectin-3 protein has recently been impli cated in the pathogenesis of NASH. Galectins 
are a family of proteins, containing 15 memb ers (11 identified in humans), which have the 
property of binding avidly to galactose containing oligosaccharides associated with 
glycoproteins ( Di 2011). GR-MD-02 (galactoarabino- rh amnogalacturnate) represents a new 
type of agent for the therapy of subjects with NASH and advanced fibrosis. GR-MD-02 is a 
complex carbohydrate molecule derived from a natural plant compound which contains 
oligosaccharide chains containi ng galactose residues and binds to galectin-3, and to a lesser 
extent, galectin-1. Cellular experiments demonstr ate that GR-MD-02 is not toxic to cells but 
is capable of inhibiting the expression of in flammatory cytokines in a monocyte/macrophage 
model of inflammation and reduces  cell surface galectin-3 from fibrogenic liver stellate cells. 
GR-MD-02 has been tested in 2 models of liver fibrosis, a mouse model that reliably produced a pathological pi[INVESTIGATOR_21672] a fibrosis and a toxin-induced model of liver 
fibrosis in rats. Multiple studies were completed in the mouse NASH model that showed that 
GR-MD-02 consistently reduced the activity of NASH, reduced or eliminated fibrosis as 
24
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 24 measured by [CONTACT_21709], and reduced the ex pression of galectin-3  in liver macrophages 
(Traber 2013a). Much more robust fibrosis and cirrh osis were induced in rats treated with 
thioacetamide in which animals developed fibr osis that replaced 25% of the liver with 
collagen and had all of the pathological characteristics of cirrhosis. Treatment of cirrhotic rats 
with 4 weekly doses GR-MD-02 resulted in redu ction of collagen to below 10%, reversal of 
cirrhosis, and reduced portal hypertension (Traber 2013b). 
The results from a Phase 1 study ( Galectin  2014) indicated GR-MD-02 was safe and well 
tolerated at single and multiple doses of 2, 4, and 8 mg/kg. Pharmacokinetics revealed drug 
exposure in humans at the 8-mg/kg dose that  was equivalent to the upper range of the 
targeted therapeutic dose determined from ef fective doses in NASH animal models, thus 
providing support for the proposed Phase [ADDRESS_20574]® (FibroSure®) 
scores due to a reduction in alpha-2 macroglobulin levels. Additionally, there was a signal of 
reduced liver stiffness as assessed by [CONTACT_21699]® in subjects treated with an 8-mg/kg dose of 
GR-MD-02. 
25
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 25 2 Study Objectives 
2.1 Primary Objective 
The primary objective is to evaluate the ef ficacy of GR-MD-02 on reducing hepatic venous 
pressure gradient (HVPG) as a measure of portal pressure comp ared to placebo at 1 year of 
treatment. 
2.2 Secondary Objectives 
The secondary objectives of this study are to evaluate differences  in relevant assessments of 
fibrosis and cirrhosis between GR-MD-02-treated and placebo-treated subjects.  
26
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 26 The secondary objectives are to evaluate: 
• The effect of GR-MD-02 on change in the collagen proportional area (CPA) at 
1 year compared to placebo as determined  by [CONTACT_21710] 
• The effect of GR-MD-[ADDRESS_20575] infusion, at Infu sion Visit 13, and 14-28 days after final 
infusion as compared to placebo 
• The effect of GR-MD-[ADDRESS_20576] 30 (percentage dose recovery) value of the 13C-methacetin breath test 
(MBT) (if available) at sc reening, at Infusion Visit 13, and 14-28 days after final 
infusion as compared to placebo 
• The effect of GR-MD-02 on progression of cirrhosis at 1 year as compared to 
placebo, defined as the development of any of the following:  
o esophageal variceal hemorrhage or  portal hypertensive gastropathy 
hemorrhage (confirmed by [CONTACT_21700]) 
o clinically apparent ascites  
o spontaneous bacterial peritonitis 
o overt hepatic encephalopa thy (defined by [CONTACT_21711], but should include the presence of lethargy, 
disorientation, inappropriate behavior , and the presence of asterixis) 
o an increase in Child-Turcotte-Pugh score ≥[ADDRESS_20577] without pr ior varices  
o progression from small to medium or large varices  
o reaching a model for end-stag e liver disease (MELD) score ≥15 as 
measured on 2 consecutive occasions 
o listing for a liver transplant or the performance of a liver transplant 
o liver-related mortality 
 
27
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 27 2.3 Exploratory Objectives 
The exploratory objectiv es are to evaluate: 
• Difference in health-related quality of life using the subject-completed chronic 
liver disease questionnaire (CLDQ) following administration of GR-MD-02 or 
placebo at 1 year 
• Baseline-adjusted change in FibroTes t (FibroSure) and th e enhanced liver 
fibrosis (ELF) score at Infusion Visits   7, 13, 20, and 14-28 days after final 
infusion 
• Changes in liver biopsy staining for alpha smooth muscle actin and galectin-3 in 
subjects treated with GR-MD-02 or placebo at 1 year 
2.4 Safety Objectives 
The safety objectives are to assess the safety  and tolerability of GR-MD-02 versus placebo at 
1 year. 
2.5 Pharmacokinetic Objective 
The pharmacokinetic (PK) objectives are to evaluate systemic exposure following multiple 
doses of GR-MD-[ADDRESS_20578] s with portal hypertension due to NASH cirrhosis and to 
explore the population pharmacokinetics of GR -MD-02 in subjects with NASH with portal 
hypertension and cirrhosis or ad vanced bridging fibrosis.  
Note: Formal population PK analysis will not  be performed in this study. However, 
GR-MD-02 plasma levels will be used to evaluate systemic exposure following multiple doses. In the Phase 1 clinical study ( Galectin  2014), the observed maximum plasma or serum 
concentration after administration (C
max) drug levels for all doses were well correlated with 
the area under the concentr ation-time curve (h*µg/mL) (p<0.001, r squared = 0.91). 
Therefore, C max plasma levels at [ADDRESS_20579] 
(IMP) infusion at Infusion Visits 1, 2, 3, 4, 7, 10, 13, and 26. Trough levels of drug will not 
be informative, since there were only meas urable levels of drug detected through 72 hours 
following a dose and were thereafter undetectable  (assay limit of detection of 1.2 µg/mL).  
28
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20580] s with portal hypertension due to advanced 
bridging fibrosis or cirrhosis. The study will be conducted in 45 to 60 study centers in the 
[LOCATION_002] and Canada.  
This study will enroll subjects with portal hypertension (HVPG greater than or equal to 
6 mm Hg) who also have a liver  biopsy showing cirrhosis (Isha k stage 5 or 6), or advanced 
bridging fibrosis (Ishak stage 4) presumably  due to NASH, excluding subjects with medium 
and large varices and those with decompensa ted cirrhosis (as defined by [CONTACT_21712], any epi[INVESTIGATOR_21673], and overt hepatic 
encephalopathy). Subjects with portal hyperten sion and the appropriate biopsy findings will 
be randomly assigned (1:1:1) to receive 1 of 3 treatment assignments: placebo, GR-MD-02 in 
a dose of 2 mg/kg lean body mass, or GR-M D-02 in a dose of 8 mg/kg lean body mass 
administered every other week over a 52-w eek period for a total of 26 infusions ( Figure 3-1). 
The primary endpoint analysis is the base line-adjusted change in HVPG at 1 year 
(53 - 55 weeks) in subjects treated with plac ebo as compared to subjects treated with 
GR-MD-02 (2 mg/kg/week or 8 mg/kg/week). The model will include treatment group at 
randomization and the baseline HVPG as a covariate. 
29
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 29 Figure 3-1 Study Design GT-026 
Prescreening  (Week  -9) 
& 
Screening Evaluation 
(up to 8 weeks)
Medium &
Large
VaricesPlacebo
GR-MD-02 (2 mg/kg)
GR-MD-02 (8 mg/kg)
EGD
HVPG
LB
EGD
HVPG
LB26 
every 
other week 
infusionsWeek 
53-55Week 1
EOS 
Week 
57
 
Abbreviations: EGD, esophagogastroduodenoscopy; HVPG, hepatic venous pressure gradient; LB, liver biopsy 
(percutaneous or transjugular) 
The study will include prescreening, screeni ng, randomization, treatment, and follow-up 
periods. No dose modification for GR-MD-02 will be allowed. 
A flow chart depi[INVESTIGATOR_21674] a nd screening procedures is provided in Figure 3-2 . 
30
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 30 Figure 3-2 Prescreening and Screening Flow Chart GT-026 
Previous liver biopsy 
with NASH with 
cirrhosis  (Ishak stage 5 
or 6) or advanced 
bridging fibrosis (Ishak 
stage 4)
EGD*
Clinical diagnosis of 
NASH with FibroScan® 
score ≥ 12 kPaMedium or large 
varices or varices 
with red signs
No varices or 
small varicesDoes not 
qualify 
for study 
inclusion
Does not 
qualify 
for study 
inclusionHVPG measurement 
and liver biopsy*
•HVPG ≥ 6 mmHg
•Liver biopsy with 
Ishak stage 4, 5, or 6 fibrosis consistent 
with NASH
RANDOMIZATIONYesNoYes
NoYesNonlaboratory and 
laboratory inclusion 
and exclusion 
criteria met
 
Abbreviations: EGD, esophagogastroduodenoscopy; HVPG, hepatic venous pressure gradient; NASH, 
nonalcoholic steatohepatitis 
Note: 13C-methacetin breath test (if available) to be performed before either EGD, liver biopsy, or HVPG at 
investigator’s discretion. 
 
Prescreening: Prescreening may begin at Week –9.  Prior to beginning prescreening 
procedures, the subject must sign the informed consent form (ICF).  Criteria have been 
established to avoid unnecessary medical procedures (HVPG, esophagogastroduodenoscopy 
[EGD] and biopsy) in subjects who have a high likelihood of not meeting key study 
requirements. Subjects who have had a previous liver biopsy with a diagnosis of NASH with 
either advanced bridging fibrosis (Ishak stage 4) or cirrhosis (Ishak stage 5 or 6) are eligible 
to move forward to screening. Subjects with  a presumptive clinical diagnosis of NASH 
(based on the assessment of the principal investigator) will have  a FibroScan to assess the 
potential for fibrosis. Subjects who have a Fibr oScan score of at leas t 12.0 kiloPascals (kPa) 
will be considered to have advanced fibrosis and will proceed to screening. Likewise, subjects with a documented qualifying FibroScan  score within the pr evious 12 months of 
screening may proceed to screening. 
31
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 31 Screening : The screening window is up to 8 weeks.  
Subjects will undergo the following required pr ocedures to assess eligibility during the 
screening period: HVPG measurement, liver biop sy, and EGD. Additionally, at the time of 
1 of these 3 procedures (at the discretion of the investigator), subjects will have a MBT 
performed (if available) prior to the procedur e. Eligible subjects will have both an HVPG 
screening measurement of at least 6 mm Hg and a liver biopsy with advanced bridging 
fibrosis (Ishak stage 4) or cirrhosis (Ishak stage 5 or 6), presumably due to NASH. Central 
reading groups will be used to assess the appropriateness of biopsy and HVPG 
measurements. A liver biopsy diagnosis of a dvanced bridging fibr osis or cirrhosis, 
presumably due to NASH, will include the following 2 categories:  
1. Cirrhosis or advanced bridging fibrosis w ith a definitive pathological diagnosis of 
NASH (presence of fat, ballooning de generation, and inflammation) or; 
2. Cirrhosis or advanced bridging fibrosis wherein the subject has greater than 5 years of 
obesity (body mass index [BMI ] >30) and/or diabetes with negative viral hepatitis 
markers and a biopsy showing cirrhosis or advanced bridging fibrosis with any 
amount of fat 
Subjects who meet all of the inclusion criteria and none of the ex clusion criteria will proceed 
to randomization and the treatment phase. Subjects  who fail to meet elig ibility criteria due to 
an abnormal laboratory result may undergo rete sting of the abnormal laboratory parameter 
during the screening window and at  the discretion of the investig ator and with prior approval 
of the medical monitor.  
Treatment Phase : Subjects with portal hypertension who meet all of the other criteria for 
study inclusion will be randomly assigned (1:1:1 ) to receive 1 of 3 treatment assignments 
including placebo, GR-MD-02 in a dose of 2 mg/kg lean body mass, or GR-MD-02 in a dose 
of 8 mg/kg lean body mass administered every ot her week over a 52-week period for a total 
of 26 infusions. During the treatment phase of  the study, all subjects randomly assigned to 
IMP will attend study visits according to the schedule of visits for study administration and 
monitoring ( Table 12-2 ). Safety (12-lead electrocardiogr am [ECG], physical examinations, 
vital sign measurements, adverse event [AE] monitoring, and safe ty laboratory assessments), 
and efficacy (FibroScan, MBT (if available), biomarkers, assessment of cirrhosis complications [esophageal variceal hemorrhage or portal hypertensive gastropathy 
32
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 32 hemorrhage, clinically apparent ascites, spont aneous bacterial perit onitis, overt hepatic 
encephalopathy, listing for a liver transplant or  the performance of a liver transplant], and 
quality of life) will be monito red throughout the treatment phase. 
Postdose Final Visit (14-28 days) : All subjects will attend a vis it (or visits) 14 to 28 days 
after final dose. During this visit, safety (AE monitoring and safety laboratory assessments) 
and efficacy (FibroScan, MBT [if available], biomarkers, EGD, HVPG, and a liver biopsy) 
assessments will be collected/performed ( Table 12-2 ).  
Follow-up/Early Termination Visit : All subjects are to attend a follow-up/early termination 
visit 14 days after the postdose fi nal visit to evaluate safety. During this visit, a 12-lead ECG , 
a physical examination, vital sign measurements, and AE monitoring will be 
collected/performed ( Table 12-2 ). 
Open-Label Extension Study : Following study completion, subjects will be offered 
enrollment into a subsequent separate study, an  open-label extension study (OLES), if there 
is adequate tolerability and no safety issues or  signs of clinical progr ession that would require 
discontinuation.  
End-of-Study Telephone Contact: [CONTACT_21713] 6 months for 2 year s, and annually thereafter for a total of 
4 years, for a brief update and ar e to be assessed for survival, listing for a liver transplant or 
the performance of a liver transplant, or complications of chronic liver disease (ascites, 
spontaneous bacterial peritonitis, variceal bleeding, and encephalopathy; Table 12-3 ). 
3.1.1 Rationale of Study Design  
Nonalcoholic steatohepatitis is a chronic inflammatory disease of the liver characterized by 
[CONTACT_21714] a subset of subjects. Cirrhosis results 
in portal hypertension, the comp lications of which (varicea l hemorrhage, ascites with 
bacterial peritonitis, hepatic encephalopathy) can result in death or the need for liver 
transplantation. There are curr ently no medical therapi[INVESTIGATOR_014] a pproved for NASH or for portal 
hypertension by [CONTACT_21715], and th is therapeutic area re presents an area of 
significant unmet medical need. Galectin-3, a protein that binds to  galactose-containing 
oligosaccharides, has been shown to be cri tical in the pathophysio logy of NASH and liver 
fibrosis. GR-MD-02, a complex carbohydrate drug that binds to galectin-3, has shown robust 
33
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 33 efficacy in preclinical models of NASH and liver  fibrosis and was safe and well tolerated in 
Phase 1 studies. Therefore, the overall objective of  this clinical study is to establish the safety 
and efficacy of GR-MD-02 as compared to placebo in the reduction of portal pressure as a 
surrogate for a reduction in fibrosis in subj ects with compensated cirrhosis due to NASH. 
Two doses of GR-MD-02 will be evaluated in this clinical study, 2 mg/kg and 8 mg/kg lean 
body weight. The doses are calculated on lean body weight because the drug is distributed 
primarily in the blood compartment. These 2 doses  were chosen because the drug exposure in 
humans based on area under the concentration-time curve spans the predicted therapeutic 
range determined in preclinical studies. Th e dose of 2 mg/kg is lower than the lowest 
effective dose evaluated in the preclinical NAS H model and 8 mg/kg is in the upper range of 
the therapeutic window. 
GR-MD-[ADDRESS_20581] authorities in the field 
believe and the US Food and Drug Administratio n (FDA) advised that [ADDRESS_20582].  
GR-MD-02 will be compared to a placebo in fusion consisting of vials of placebo 
(phosphate-buffered saline) diluted in [ADDRESS_20583] been shown to be effective for the treatment  of liver fibrosis in humans and, therefore, 
placebo is an appropriate comparator. 
34
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20584] meet all of the following criteria to  be enrolled in this study: 
1. Has a HVPG measurement ≥6 mm Hg. 
2. Has a liver biopsy with advanced bridging fibr osis (Ishak stage 4) or cirrhosis (Ishak 
stage 5 or 6), presumably due to NASH. A liver biopsy diagnosis of advanced bridging 
fibrosis or cirrhosis, presumably due to NASH will include the following 2 categories:  
a. Advanced bridging fibrosis or cirrhosis with a definitive pathological diagnosis of 
NASH (presence of fat, ballooning de generation, and inflammation) or;  
b. Advanced bridging fibrosis or cirrhosi s wherein the subject has greater than 
5 years of obesity (BMI >30)  and/or diabetes with nega tive viral hepatitis markers 
(hepatitis B and hepatitis C) and a biopsy showing any amount of fat. 
3. Is ≥18 years of age and ≤[ADDRESS_20585] result prior to 
randomization. 
35
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 35 6. If a fertile man or woman participating in heterosexual relati ons, agrees to use 
effective means of contraception (ie, [ADDRESS_20586] be a physical barrier method). 
• Effective forms of contraception incl ude condom, hormonal methods (birth 
control pi[INVESTIGATOR_3353], injections or implants), diaphragm, cervical cap, or intrauterine 
device throughout his/her pa rticipation in this st udy and for [ADDRESS_20587] on the same dose of the medication for the 
duration of study participation. 
4.1.2 Exclusion Criteria 
Subjects meeting any of the following crit eria will be excluded from the study: 
1. Has a history of hepatic decompensation in cluding any epi[INVESTIGATOR_21675], 
clinically detectable ascites,  or overt hepatic encephalopa thy (defined by [CONTACT_21716], 
disorientation, inappropriate behavior , and the presence of asterixis). 
36
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 36 2. Has a presence of medium or large varices or  varices with red signs regardless of size 
based on endoscopy. 
• Small varices are defined by [CONTACT_21717] o ccupy >25% of the di stal one third of 
the esophageal lumen when insufflated. Veins that completely flatten upon 
insufflation of the esophagus are not conser ved varices. Any varices larger than 
that are medium (up to 50%) or large (>50%).  
• Red signs include red wale markings (dil ated venules oriented longitudinally on 
the variceal surface), cherry red spots (small, red, spotty  dilated venules usually 
approximately 2 mm in diameter on the variceal surface) or hematocystic spots 
(large, round, crimson red projection >3 mm that look like a blood blister on the 
variceal surface). 
3. Has had a prior transjugular por to-systemic shunt procedure. 
4. Has evidence of other forms of chronic live r disease including vira l hepatitis B or C, 
primary biliary cirrhosis, primary sclerosi ng cholangitis, Wilson’s disease, alpha-1 
antitrypsin deficiency, alcoholic hepatitis, hemochromatosis, liver cancer, history of 
biliary diversion, or autoimmune hepatitis. 
5. Has any of the following laboratory values: 
a. Serum alanine aminotransferase levels >10 × the upper limits of normal 
b. Serum aspartate aminotransferase leve ls >10 × the upper limits of normal 
c. Serum creatinine ≥2.0 mg/dL  
d. Platelet count <60 000/mm3  
e. Serum albumin ≤2.8 g/dL 
f. International normalized ratio (INR) ≥1.[ADDRESS_20588] bilirubin ≥2.0 mg/dL 
6. A MELD score ≥15 or Child-Turcotte-Pugh Class B or C. 
37
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 37 7. Is unwilling or unable to safely  undergo HVPG or liver biopsy. 
8. Has known positivity for human immunodeficiency  virus (HIV) infection or a positive 
HIV test result at screening. 
9. Has had major surgery within [ADDRESS_20589] 3 years or plans to undergo weight 
reduction surgery during the study. 
14. Has current, significant alcohol consumpti on or a history of significant alcohol 
consumption for a period of more than 3 consecutive months any time within 1 year 
prior to screening. 
• Significant alcohol consump tion is defined as more than [ADDRESS_20590] drink in the [LOCATION_002] is considered  to be 14 g of alc ohol equivalent to 
12  fluid oz of regular beer (5% alco hol), 5 fluid oz of table wine (12% 
alcohol), or 1.5 fluid oz of 80 proof spi[INVESTIGATOR_2120] (40% alcohol).  
A score of ≥[ADDRESS_20591] (AUDIT) 
(Babor 2000) will result in exclusion.  (The AUDIT is provided in 
Section 12.2 .)  
15. Has a positive urine screen result for amphetamines, cocaine, or nonprescription 
opi[INVESTIGATOR_858] (heroin, morphine) at screening. 
38
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 38 16. Has clinically significant and uncontrolled cardiovascular disease (eg, uncontrolled 
hypertension, myocardial infarction within 6 months prior to randomization, unstable 
angina), [LOCATION_001] Heart Association Grade II or greater congestive heart failure, serious cardiac arrhythmia requi ring devise/ablation or Grad e II or greater peripheral 
vascular disease within [ADDRESS_20592] a poor candidate  for inclusion into the study. 
18. Has concurrent infection including diagnoses  of fever of unknown origin at the time of 
randomization (subjects must be afeb rile at the start of therapy). 
19. Has a history of malignancy, except for the following adequately treated nonmetastatic 
basal cell skin cancer; any ot her type of skin cancer, except melanoma, that has been 
adequately treated and has not recurred for at least 1 year prior to enrollment; and 
adequately treated in situ cervical cancer that  has not recurred for at least 1 year prior 
to screening. 
20. Participates in an investigational ne w drug study within 30 days prior to 
randomization (including follow-up visits) or at any time duri ng the current study. 
21. Has a clinically significant medical or psychiatric conditi on considered high risk for 
participation in an investigational study. 
22. Fails to give informed consent. 
23. Has known allergies to the IMP or any of its excipi[INVESTIGATOR_840]. 
24. Is an employee or family member of the investigator or study  center personnel. 
25. Needs concomitant use of drugs with a narrow therapeutic window metabolized by 
[CONTACT_9058] P450 3A4 (CYP3A4) isozyme including specifically the fast-acting 
opi[INVESTIGATOR_21676]; the immunosuppressive drug s cyclosporine, sirolimus, 
and tacrolimus; the cardiovascular agents ergotamine, quinidine, and 
dihydroergotamine; and the psychotropic agent pi[INVESTIGATOR_3924]. 
39
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20593] IMP 
infusion. 
4.2.1 Reasons for Withdrawal/Discontinuation 
Subjects may withdraw from the study at any time and for any reason without prejudice to 
their future medical care by [CONTACT_21718]. Ev ery effort should be 
made to keep subjects in the study. The reasons for subjects not completing the study will be 
recorded. A subject may be withdrawn from the study for any of the following reasons: 
1. Significant noncompliance with the protocol 
2. A serious or intolerable AE(s) that, in the investigator’s opi[INVESTIGATOR_21677], requires withdrawal 
from the study 
3. Laboratory safety assessments that reveal clinically significant hematological or 
biochemical changes from the baseline values 
4. Symptoms or an intercurrent illness not cons istent with the protocol requirements for 
study participation or that  justifies withdrawal 
5. Lost to follow-up 
6. Pregnancy 
7. The subject withdraws consent or the investigator or spons or decides to discontinue 
the subject’s participation in the study. 
The investigator will also wit hdraw subjects if Galectin Therapeutics Inc terminates the 
study. Upon occurrence of a serious or intolerabl e AE, the investigator will confer with the 
sponsor. If a subject is discontinued because of  an AE, the event will be followed until it is 
resolved. Any subject may withdraw his or her consent at any time. 
40
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20594] withdraws from th e study, the reason(s) for withdrawal shall be 
recorded by [CONTACT_21719] (eCRF). 
Whenever possible, all subject s who discontinue study treatment  or withdraw from the study 
prematurely will undergo all end-of-study assessmen ts. Subjects who fail to return for final 
assessments will be contact[CONTACT_21720] (2 documented telephone calls followed by 
1 registered letter) in an attempt to have them comply with the protocol. 
It is vital to obtain follow-up data on any subj ect withdrawn because of an AE or serious AE 
(SAE). In every case, efforts must be made to undertake protocol-specified, safety, follow-up 
procedures. 
4.2.3 Replacements 
Subjects who are randomly assigned to IMP an d prematurely discontinued from the study 
will not be replaced. 
41
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 41 5 Study Treatments 
5.1 Method of Assigning Subjects to Treatment Groups 
Subjects will be randomly assigned to rece ive 2 mg/kg lean body weight of GR-MD-02, 
8 mg/kg lean body weight of GR-MD-02, or pl acebo using a 1:1:1 allocation ratio. An 
interactive web response system (IWRS) will be used to administer the randomization 
schedule. Unblinded biostatistics personnel not participating in the c onduct of the study will 
generate the randomization schedule using SAS so ftware Version 9.2 or later (SAS Institute 
Inc, Cary, North Carolina) for IWRS, which will link sequential subject randomization numbers to treatment codes.  
The IWRS will send vis it notifications to the study cente r personnel confirming the subject 
data that were entered. All study visits will have a visit window of  ± [ADDRESS_20595] erile aqueous solution of phosphate-buffered 
saline at a concentration of 30 mg/mL GR-MD-[ADDRESS_20596] is expected to be stable at pH 4.0 to 7.5.  GR-MD-02 solution will be supplied in 10-mL vials with the following composition to the 
study center ( Table 5-1 ). 
Table 5-1 Composition of GR-MD-02 Concentrate 
Ingredient Concentration 
GR-MD-02  300 mg  
USP sodium chloride  82 mg  
USP disodium phosphate heptahydrate 14.4 mg  
USP monosodium phosphate monohydrate 2.4 mg  
USP sterile water for injection  to 10 mL  
Instructions on dosing preparation are provided in the Pharmacy Manual. 
42
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 42 Once the infusion solutions are prepared, they  may be stored at a room temperature 
(20°C-25°C [68°F-77°F]) and should be admi nistered within 24 hours of preparation. 
Infusions should be administered intravenously  over a period of approximately 60 minutes. 
Frequency of administration should be once every 2 weeks ( Table 12-2 ). 
5.[ADDRESS_20597] 
GR-MD-02 (galactoarabino-rhamnogalacturnate) is  a soluble polysaccharide composed of an 
alternating α-(1,2)-L-rhamnosyl- α-(1,4)-D-galacturonosyl backbone with side branches 
composed of mainly galactose and arabinose oligosaccharides.  
GR-MD-02 for injection is a clear, light yellow-t an solution and is supplied in 10-mL sterile 
vials at a concentration of  30 mg/mL of GR-MD-02 in phosphate-buffered saline.  
Detailed instructions for the preparation and administration of the GR-MD-02 by [CONTACT_21721] (IV) drip over a period of approximately 60 minut es will be provided in the 
Pharmacy Manual.  Lean body mass (LBM) will be used for dosing b ecause it is anticipated that many subjects 
will be obese and GR-MD-[ADDRESS_20598] been 
well-validated in obese individuals ( Janmahasatian 2005): 
• Males: LBM = 9270 × TBW (total body weight)/(6680 + 216 × BMI) 
• Females: LBM = 9270 × TBW/(8780 + 244 × BMI) 
Total body weight is in kilograms and BMI is in mass (weight in kilograms)/(height in 
meters
2). Tables of LBM values for a range of heights and weights will be provided to the 
pharmacies participating in the study as a check for the calculations. 
The study pharmacist at each study center will be unblinded in the preparation of IMP for 
infusion. Infusion solutions will be prepared as specified in the Pharmacy Manual in IV bags 
and placed in amber-colored IV bag covers w ith amber-colored tubing and infusion sets. The 
amber-colored bags will be sealed with tamper-evident tapes. Once prepared by [CONTACT_21722], the placebo and drug solu tions in the IV infusion set-up will be 
indistinguishable. Thus, the study subjects, primar y investigators, and medical personnel will 
43
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20599] Packaging and Storage 
Galectin Therapeutics Inc will provide IMP to  the study centers. The following drug supplies 
will be used in the study: 
• GR-MD-02, supplied as 10-mL sterile vials 
• Placebo (phosphate-buffered saline solutio n), supplied as 10-mL sterile vials 
GR-MD-02 for injection (30 mg/mL) and placebo to be used for the study 
(phosphate-buffered saline) in 10-mL vials are manufactured by [CONTACT_3339], 
Woodstock, Illinois, and packaged and labele d for the study center by [CONTACT_21723], Philadelphia, Pennsylvania. 
The GR-MD-02 for injection (30 mg/mL) vials and placebo vials are to be stored under 
refrigerated conditions at 2°C to 8°C (36°F-46°F) until prep aration of the drug infusion 
solution. To prepare the final infusion solu tion for administration, the GR-MD-[ADDRESS_20600] be recorded to indicate no unblinding 
occurred. At the completion of the study, to satisfy regulatory requirements regarding drug 
accountability, IMP will be reconciled and reta ined or destroyed according to applicable 
regulations. 
44
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 44 5.4.3 Other Supplies 
In addition to drug and placebo for the study, e ach study center will also  be provided sterile 
syringe filters, amber-colored bag covers (with tamper-evide nt tape) and amber-colored 
infusion tubing sets. See the Pharmacy Manual fo r the specifications and details regarding 
these ancillary supplies. 
5.[ADDRESS_20601] be promptly reported to  [COMPANY_003] Pharmacovigilance:   
• SAE Hotline: [PHONE_342] 
• SAE Fax line: [PHONE_343] 
Overdoses without signs or symptoms do not need to be recorded as AEs; in case of any AEs 
associated with the overdose, th ese should be reported  in relevant AE/SAE sections in the 
eCRF. 
5.5.[ADDRESS_20602] 
should be observed, but there are no specific therapi[INVESTIGATOR_21678]. 
5.5.2 Medication Errors 
A medication error is any uninten tional error in prescribing, di spensing, or administration of 
the IMP. The IMP will be prepared and admini stered at the study center by [CONTACT_21724], 
thereby [CONTACT_21725]. 
Acceptable treatment windows for infusions will be ± 3 days. Infusions given outside of 
accepted windows will be considered “out-of-wi ndow” doses. If a dose is out of window, the 
subject should be brought back into compliance with his or her visit dosing schedule. The 
subject should not dose within 7 days of the previous or next  dose unless the medical monitor 
is consulted and agrees. 
45
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20603] should be obser ved; however, there are no 
specific therapi[INVESTIGATOR_21678]. 
5.[ADDRESS_20604]’s treatment assignment will not be broken until the end of the study unless medical treatment of the subject depends  on knowing the study treatment the subject received. In the 
event that the blind needs to be broken because of a medical emergency, the investigator may unblind an individual subject’s treatment allocation. As soon as  possible, the investigator 
should first contact [CONTACT_21726]. The treatment assignment will be 
unblinded by [CONTACT_21727]. Reasons for treatment unblinding must be clearly explained and justified in the eCRF. The date on which the code was broken together 
with the identity of the person responsible must also be documented. 
46
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20605] compliance will be dete rmined by [CONTACT_21728].  
Acceptable windows for IMP dosing are ± 3 da ys. Infusions given outside of accepted 
windows will be considered “out-of-window” doses . If a dose is out of window, the subject 
should be brought back into compliance with hi s or her visit dosing schedule. The subject 
should not dose within [ADDRESS_20606]’s eCRF. The minimum 
requirement is that drug name, reason for use, dose, and the dates of administration will be 
recorded. This will include all prescription drugs, herbal products, vitamins, minerals, and over-the-counter medications. Any changes in co ncomitant medications will also be recorded 
in the subject’s eCRF. 
All prior treatments for liver cirrhosis and NASH will be recorded in the eCRF. All other 
concomitant medications taken from [ADDRESS_20607]’s participation in the study will be documented in the eCRF. 
Concomitant medications are defined as medications taken any time after the start of 
exposure to IMP. Prior medications are defi ned as nonstudy medications discontinued prior 
to the start of exposure to IMP. 
Any concomitant medication deemed necessary for the welfare of the subject during the 
study may be given at the discretion of the invest igator. If prohibited medications are needed 
for the welfare of the subject, the subject shou ld be discontinued from the study. It is the 
responsibility of the investigator to ensure that details regard ing the medication are recorded 
in full in the eCRF. 
5.[ADDRESS_20608]-acting opi[INVESTIGATOR_21679]; the immunosuppressive 
drugs cyclosporine, sirolimus, and tacrolim us; the cardiovascular agents ergotamine, 
quinidine, and dihydroergotamine; and the psycho tropic agent pi[INVESTIGATOR_3924]. In vitro experiments 
47
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20609] shown some inhibition of  CYP3A4 enzyme expression a nd activity at levels of drug 
exposure much higher than obtained in this study. A human drug-drug interaction study is 
being conducted to evaluate whether there ar e any changes in in th e pharmacokinetics of a 
model CYP3A4-metabolized drug. Once the results of this study are available, this exclusion 
criterion may be modified. 
Nonselective β-adrenergic inhibitors for the purpose of treatment of portal hypertension are 
prohibited during the study as well as any off-label drugs. 
48
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20610] information not mandated to be present in this protocol is 
provided in the accompanying Study Manual/Inve stigator Site File Notebook which will 
provide the study center personnel with administra tive and detailed technical information that 
does not impact subject safety. 
Before any study procedures are performed, all pot ential subjects will sign an ICF. Subjects 
will have the opportunity to have any questi ons answered before signing the ICF. The 
investigator must address all questions raised  by [CONTACT_423]. The investigator will also sign 
the ICF. 
The schedule of events for  prescreening and screening is provided in Table 12-1, for 
randomization, treatment phase, and follow-up in Table 12-[ADDRESS_20611] in Table 12-3.  
6.1 Study Visits 
6.1.1 Prescreening Visit (Week –9) 
After the subject has provided informed consent, the following information will be collected 
(Table 12-1 ): 
• Enter the IWRS and regist er subject visit data. 
• NASH diagnosis: Subjects who have ha d a previous liver biopsy with a 
diagnosis of NASH with either advanced bridging fibrosis (Ishak stage 4) or 
cirrhosis (Ishak stage 5 or 6) are elig ible to move forward to screening. 
• Conduct a FibroScan: Subjects with a presumptive clin ical diagnosis of NASH 
(based on the assessment of the principal investigator) will have a FibroScan to 
assess the potential of fibrosis. Subj ects who have a FibroScan score of 
≥12.[ADDRESS_20612] a dvanced fibrosis and will proceed to 
screening. Likewise, subjects with a documented qualifying FibroScan score 
within the previous 12 months of sc reening may proceed to screening. 
49
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 49 6.1.2 Screening Visit (Week -8 to Day 0) 
The screening visit window is up to 8 weeks after the prescreen ing visit. Subjects who fail to 
meet eligibility criteria within  this 8-week period due to an abnormal laboratory result may 
undergo retesting of the abnormal laboratory pa rameter during the screening window and at 
the discretion of the investigat or and with prior approval of the medical monitor. During the 
screening visit, the following information will be collected ( Figure 3-2  and Table 12-1 ): 
• Enter the IWRS and regist er subject visit data. 
• Inclusion/exclusion criteria include AUDIT alcohol consumption questionnaire. 
The AUDIT is a screening tool to iden tify the early signs of hazardous and 
harmful drinking and identify mild dependence. This questionnaire 
(10 questions total) will be given to the subject at the beginning of the screening 
visit and will be considered source documentation. The subject will sign and 
date the questionnaire upon completion. 
• Collect demographic information. 
• Collect medical, surgical, and medica tion history (concomitant medications 
taken from 30 days prior to screening). 
• Perform a 12-lead ECG assessment. 
• Perform hematology testing. 
• Perform blood chemistry testing. 
• Perform coagulation profile. 
• Obtain MELD score. 
• Perform viral hepatitis B and C serology. 
• Perform HIV serology. 
50
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 50 • Perform urine drug screen for amphet amines, cocaine, and nonprescription 
opi[INVESTIGATOR_858]. 
• Perform urinalysis testing. 
• Perform serum pregnancy test (femal es of childbearing potential only). 
• Perform chest radiograph (posteri or-anterior and lateral views). 
• Obtain Child-Turcotte-Pugh score and class (A, B, or C). 
• Perform a complete physical examination (including height [in centimeters] and 
weight [in kilograms]) with particular at tention to examination for stigmata of 
liver disease/cirrhosis. 
• Collect vital sign measurements (including heart and respi[INVESTIGATOR_697], blood 
pressure, and body temperature). 
• Perform MBT (if available) prior to EGD, HVPG, or liver biopsy (at the 
discretion of the investigator). 
• EGD  Subjects will have had an EGD within  2 months prior to randomization. 
Subjects with medium or large varices or  varices with red signs (red wale marks 
or red spots), regardless of size, w ill be excluded from study participation. 
Subjects without varices or with sm all varices will continue to HVPG 
measurement and liver biopsy.  
• Obtain demographic information. 
• HVPG  Subjects must have both an HVPG measurement ≥6 mm Hg and a liver biopsy 
with advanced bridging fibrosis (Ishak stag e 4) or cirrhosis (Ishak stage 5 or 6), 
presumably due to NASH. Subjects without  varices or with small varices will 
have hepatic venous catheterization with  measurement of both wedged and free 
hepatic venous pressures and standardized calculat ion of the HVPG prior to 
randomization and first IMP infusion. 
51
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 51 • Obtain liver biopsy  
Liver biopsy may be obtained via a perc utaneous approach or a transjugular 
approach during the HVPG procedure, at the preference of the investigator.  
• AE monitoring. 
6.1.3 Treatment Phase 
[IP_ADDRESS]  Randomization 
Randomization must occur between 3 and 8 weeks after screening ha s begun. The IWRS will 
be used to administer the randomization schedule. 
Prior to Infusion Visit 1, subjects with portal hypertension and the appropriate biopsy will be 
randomly assigned (1:1:1) to receive 1 of 3 treatment assignments: placebo, GR-MD-02 in 
dose of 2 mg/kg lean body mass, or GR-M D-02 in a dose of 8 mg/kg lean body mass. 
Subjects will be entered into the study and randomly assigned if they have both an HVPG 
screening measurement greater than or equal to  6 mm Hg and a liver biopsy with advanced 
bridging fibrosis (Ishak stage 4) or cirrhosis (Ishak stage 5 or 6), presumably due to NASH 
and meet all inclusion criteria and no exclusion criteria. 
[IP_ADDRESS]  Two Weeks Prior to Infusion Visit [ADDRESS_20613] in fusion, a FibroScan will be conducted. 
[IP_ADDRESS]  Infusion Visit 1 (Week 1) 
During the Infusion 1 Visit, the following procedures and assessments will be performed 
after randomization and prior to administration of IMP ( Table 12-2 ): 
• Enter the IWRS and regist er subject visit data. 
• CLDQ (This questionnaire will be given to the subject at the beginning of the 
visit and will be considered source documentation.) 
• Alcohol timeline followback (TLFB) (Thi s will be given to the subject at the 
beginning of the visit and will be considered source documentation.) 
52
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 52 • Perform a limited physical examination (including weight and examination of 
the heart, lung, and abdomen). 
• Collect vital sign measurements (including heart and respi[INVESTIGATOR_697], blood 
pressure, and body temperature). 
• Perform hematology testing. 
• Perform blood chemistry testing. 
• Collect biomarkers blood sample (will include the ELF test and FibroTest [FibroSure], and galectin-3). 
• Collect plasma and serum sa mple for storage at –20°C. 
The following information will be collected after IMP administration: 
• AE monitoring. 
• Record concomitant medications. 
The following will be performed 2 hours after the end of the IMP infusion: 
• Collect PK sample. 
[IP_ADDRESS]  Infusion Visits 2, 3, 4, 5, and 6 (W eeks 3, 5, 7, 9, and 11 ± 3 Days, 
respectively) 
The following procedures and assessments will be performed prior to administration of IMP: 
• Enter the IWRS and regist er subject visit data. 
• Alcohol TLFB (This will be given to the subject at the beginning of the visit 
and will be considered source doc umentation.) (Infusion Visit 5) 
• Assessment of cirrhosis complica tions (Infusion Visits 3 and 5). 
• Perform a limited physical examination (including weight and examination of the heart, lung, and abdomen). 
53
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 53 • Collect vital sign measurements (including heart and respi[INVESTIGATOR_697], blood 
pressure, and body temperature). 
• Perform urine pregnancy test (females of childbearing potential only) (Infusion 
Visits 3 and 5). 
The following information will be collected after IMP administration: 
• AE monitoring. 
• Record concomitant medications. 
The following will be performed 2 hours after the end of the IMP infusion 
• Collect PK sample (Infusion Visits 2, 3, and 4) 
[IP_ADDRESS]  Infusion Visit 7 (Week 13 ± 3 Days) 
The following procedures and assessments will be performed prior to administration of IMP: 
• Enter the IWRS and regist er subject visit data 
• Assessment of cirrhosis complications 
• Perform a limited physical examination (including weight and examination of the heart, lung, and abdomen)  
• Collect vital sign measurements (including heart and respi[INVESTIGATOR_697], blood 
pressure, and body temperature) 
• Perform urine pregnancy test (femal es of childbearing potential only) 
• Perform hematology testing 
• Perform blood chemistry testing 
The following information will be collected after IMP administration: 
• AE monitoring 
54
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 54 • Record concomitant medications 
The following will be performed 2 hours after the end of the IMP infusion 
• Collect PK sample 
[IP_ADDRESS]  Infusion Visits 8, 9, 10, 11, a nd 12 (Weeks 15, 17, 19, 21, and 23 
± 3 Days) 
The following procedures and assessments will be performed prior to administration of IMP: 
• Enter the IWRS and regist er subject visit data. 
• Assessment of cirrhosis complicatio ns (Infusion Visits 9 and 11). 
• Alcohol TLFB (This will be given to the subject at the beginning of the visit 
and will be considered source doc umentation.) (Infusion Visit 9) 
• Perform a limited physical examination including weight and examination of 
the heart, lung, and abdomen). 
• Collect vital sign measurements (including heart and respi[INVESTIGATOR_697], blood 
pressure, and body temperature). 
• Perform urine pregnancy test (females of childbearing potential only) (Infusion Visits 9 and 11). 
The following information will be collected after IMP administration: 
• AE monitoring. 
• Record concomitant medications. 
The following will be collected 2 hours after IMP infusion 
• Collect PK sample (Infusion Visit 10). 
[IP_ADDRESS]  Infusion Visit 13 (Week 25 ± 3 Days) 
The following procedures and assessments will be performed prior to administration of IMP: 
55
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 55 • Enter the IWRS and regist er subject visit data. 
• Alcohol TLFB (This questionnaire will be given to the subject at the beginning 
of the visit and will be cons idered source documentation.) 
• Assessment of cirrhosis complications. 
• Perform a limited physical examination (including weight and examination of the heart, lung, and abdomen). 
• Collect vital sign measurements (including heart and respi[INVESTIGATOR_697], blood 
pressure, and body temperature). 
• Perform urine pregnancy test (females of childbearing potential only).  
• Perform hematology testing. 
• Perform blood chemistry testing. 
• Obtain MELD score. 
• Conduct a FibroScan. 
• Perform MBT (if available). 
• Collect biomarkers blood sample (will include the ELF test, FibroTest 
[FibroSure], and galectin-3). 
• Collect plasma and serum sa mple for storage at –20°C. 
The following information will be collected after IMP administration: 
• Perform a 12-lead ECG assessment. 
• Obtain Child-Turcotte-Pugh score and class (A, B, or C). 
• AE monitoring. 
• Record concomitant medications. 
56
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 56 The following will be collected 2 hours after the end of the IMP infusion 
• Collect PK sample  
[IP_ADDRESS]  Infusion Visits 14, 15, 16, 17, 18, and 19 (Weeks 27, 29, 31, 33, 35, 
and 37 ± 3 Days) 
The following procedures and assessments will be performed prior to administration of IMP: 
• Enter the IWRS and regist er subject visit data. 
• Alcohol TLFB (This questionnaire will be given to the subject at the beginning 
of the visit and will be considered source documenta tion.) (Infusion Visit 17) 
• Assessment of cirrhosis complicatio ns (Infusion Visits 15, 17, and 19). 
• Perform a limited physical examination (including weight and examination of 
the heart, lung, and abdomen). 
• Collect vital sign measurements (including heart and respi[INVESTIGATOR_697], blood pressure, and body temperature). 
• Perform urine pregnancy test (females of childbearing potential only) (Infusion Visits 15, 17, and 19). 
The following information will be collected after IMP administration: 
• AE monitoring. 
• Record concomitant medications. 
[IP_ADDRESS]  Infusion Visit 20 (Week 39 ± 3 Days) 
The following procedures and assessments will be performed prior to administration of IMP: 
• Enter the IWRS and regist er subject visit data 
• Perform a limited physical examination (including weight and examination of the heart, lung, and abdomen) 
57
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 57 • Collect vital sign measurements (including heart and respi[INVESTIGATOR_697], blood 
pressure, and body temperature) 
• Perform hematology testing 
• Perform blood chemistry testing 
The following information will be collected after IMP administration: 
• AE monitoring 
• Record concomitant medications 
[IP_ADDRESS]  Infusion Visit 21 (Week 41 ± 3 Days) 
The following procedures and assessments will be performed prior to administration of IMP: 
• Enter the IWRS and regist er subject visit data. 
• Alcohol TLFB (This questionnaire will be given to the subject at the beginning of the visit and will be cons idered source documentation.) 
• Assessment of cirrhosis complications. 
• Perform a limited physical examination (including weight and examination of the heart, lung, and abdomen). 
• Collect vital sign measurements (including heart and respi[INVESTIGATOR_697], blood pressure, and body temperature). 
• Perform urine pregnancy test (femal es of childbearing potential only). 
The following information will be collected after IMP administration: 
• AE monitoring. 
• Record concomitant medications. 
58
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 58 [IP_ADDRESS]  Infusion Visits 22, 23, 24, and 25 (Weeks 43, 45, 47, and 49 
± 3 Days) 
The following procedures and assessments will be performed prior to administration of IMP: 
• Enter the IWRS and regist er subject visit data. 
• Alcohol TLFB (This questionnaire will be given to the subject at the beginning 
of the visit and will be considered source documenta tion.) (Infusion Visit 25) 
• Assessment of cirrhosis complica tions (Infusion Visits 23 and 25). 
• Perform a limited physical examination including weight and examination of the heart, lung, and abdomen). 
• Collect vital sign measurements (including heart and respi[INVESTIGATOR_697], blood pressure, and body temperature). 
• Perform urine pregnancy test (females of childbearing potential only) (Infusion Visits 23 and 25). 
The following information will be collected after IMP administration: 
• AE monitoring. 
• Record concomitant medications. 
[IP_ADDRESS]  Infusion Visit 26 (Week 51 ± 3 Days) 
The following procedures and assessments will be performed prior to administration of IMP: 
• Enter the IWRS and regist er subject visit data. 
• CLDQ (This questionnaire will be given to the subject at the beginning of the 
visit and will be considered source documentation.) 
• Assessment of cirrhosis complications. 
59
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 59 • Perform a limited physical examination (including weight and examination of 
the heart, lung, and abdomen). 
• Collect vital sign measurements (including heart and respi[INVESTIGATOR_697], blood 
pressure, and body temperature). 
• Perform hematology testing. 
• Perform blood chemistry testing. 
• Obtain MELD score. 
• Collect plasma and serum sa mple for freezing at –20°C. 
The following information will be collected after IMP administration: 
• Obtain Child-Turcotte-Pugh score and class (A, B, or C). 
• AE monitoring. 
• Record concomitant medications. 
The following will be collected 2 hours after the end of the IMP infusion: 
• Collect PK sample  
6.1.4 Follow-up (14-28 Days After Fina l Dose; Weeks 53-55 ± 3 Days) 
Within 14 to 28 days after the final 26th dos e of IMP or, where feasible, following study 
termination, the following information will be collected ( Table 12-2 ): 
• Enter the IWRS and regist er subject visit data 
• Perform a limited physical examination including weight and examination of 
the heart, lung, and abdomen) 
• Collect vital sign measurements (including heart and respi[INVESTIGATOR_697], blood pressure, and body temperature) 
60
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 60 • Conduct a FibroScan 
• Perform MBT (if available) 
• Collect biomarkers blood sample (will include the ELF test, FibroTest 
[FibroSure], and galectin-3) 
• Perform EGD (must be performed on a different day within the 14 to 28-day 
follow-up period than when the HVPG assessment is performed) 
• Perform HVPG 
• Obtain a liver biopsy 
• Perform hematology testing 
• Perform blood chemistry testing 
• AE monitoring 
• Record concomitant medications 
6.1.5 Follow-up/Early Termination (Week 57 ± 3 Days) 
Fourteen days after the previous visit ( Section 6.1.4 ), the following information will be 
collected (Table 12-2 ): 
• Enter the IWRS and regist er subject visit data 
• Perform a 12-lead ECG assessment 
• Perform a limited physical examination (including weight and examination of 
the heart, lung, and abdomen) 
• Collect vital sign measurements (including heart and respi[INVESTIGATOR_697], blood 
pressure, and body temperature) 
• AE monitoring 
61
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 61 • Record concomitant medications 
[IP_ADDRESS]  Open-Label Safety Extension Study 
Following study completion, subjects will be offered enrollment into a subsequent separate 
study, an OLES if there is adequate tolerability and no safety issues or signs of clinical progression that would r ecommend discontinuation.  
6.1.[ADDRESS_20614] 
Subjects who do not enroll in the OLES will be  contact[CONTACT_21702] 6 months for 
2 years, and annually thereafter for a total of 4 years, for a brief upda te. Subjects are to be 
assessed for survival, listing for a liv er transplant  or the performance of a liver transplant, or 
complications of chronic liver disease (ascites, spontaneous b acterial peritonitis, variceal 
bleeding, and encephalopathy; Table 12-3 ).  
6.[ADDRESS_20615] IMP dose. A ll HVPG pressure tracings will be performed 
according to the study guidelines provided in  the Study Manual. All HVPG tracings will be 
evaluated at a central reading facility by a single experienced  investigator ([CONTACT_21774]-Tsao, Yale University) to confirm that th e subjects meet criteria for inclusion prior to 
randomization. 
Blinded paired HVPG tracings from prior to ra ndomization and at the end of the study will 
be evaluated at the same central facility by [CONTACT_21729].  
62
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 62 6.2.2 Liver Biopsy 
Liver biopsies will be evaluated to determin e the general pathological diagnosis and to 
quantitatively evaluate the degree of liver fibr osis. In a central pat hology laboratory, paired 
biopsies from baseline and the end of treatment for each individual will be stained with Sirius 
red, which stains specifically t ype I collagen, and digital morphom etry used to quantitate the 
percentage of the liver biopsy that stains with Sirius red, as previously described 
(McHutchison 2010). The change in liver collagen (a su rrogate for fibrosis) will be measured 
by [CONTACT_21730] [ADDRESS_20616] ([CONTACT_21775], INNOV A Medical 
Center).  
In addition, as exploratory endpoints, liver biops ies will be stained with  antibodies to alpha 
smooth muscle and galectin-3  and similarly quantified ( McHutchison 2010). The change in 
staining of these [ADDRESS_20617] in 
liver tissue which is a measure of liver stiffness. The stiffness of the liver is recorded as the 
pressure measurement of kPa. The stiffness of the liver correlates with the degree of liver 
fibrosis as assessed by [CONTACT_21731] y, including subjects with NASH ( Wong 2010). One 
advantage of this method is that the volum e of liver tissue assessed is approximately 
[ADDRESS_20618] according to the study 
guidelines provided in the Study Manual and as per the manufacturer’s instructions. 
6.2.[ADDRESS_20619] 
The MBT is a noninvasive tool to assess microsomal capacity to metabolize the 
nonradioactive 13C-labeled methacetin. For those study centers where the MBT is approved, 
63
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20620] according to the study guidelines provided in 
the Study Manual and as per the manufacturer’s instructions. The study center will make a 
follow-up telephone call to the su bject to capture any AEs that  may have occurred within 
[ADDRESS_20621] System consists of the BreathID® MCS device and a test kit containing a 
breath collection cannula and a nonradioactive isotope 13C-methacetin solution. The 
BreathID device measures and computes the 13CO 2/12CO [ADDRESS_20622]’s exhaled 
breath in real time. The device is based on an FDA-approved device (510k#: K130524) for assessment of 
Helicobacter pylori  infection in the stomach utilizing 
13C-urea as a substrate. Performance 
and safety of the device utilizing the 13C-methacetin substrate for assessment of liver 
function have been studied in thousands of subjects worldwide, including in a large US 
pi[INVESTIGATOR_2397] (G080107) enrolling over 400 subjects with chronic liver disease from 
11 participating sites (incl uding 141 subjects with biopsy pr oven cirrhosis). This study 
demonstrated an excellent safety profile of  the MBT. Furthermore, there are currently 
2 ongoing studies ( G140190, G140254) for detection of clinic ally significant portal 
hypertension in subjects with advanced liver  disease and for assessment of correlation to 
severity of liver disease in subjects with NAFLD. 
The MBT parameter to be used in the current study is the cPDR 30, which is th e cumulative 
percentage dose recove ry of the metabolized 13C-methacetin [ADDRESS_20623] substrate. It is obtained by [CONTACT_21732]: 
1. All delta over baseline (DOB) m eas ures with corresponding tim e point (T n) will be 
noted on the eCRF. Ea ch DOB wi ll be pl otted by [CONTACT_21733]:  
DOB = 13CO 2/12CO 2 @T n - 13CO 2/12CO 2 @T 0 
where T 0 is the baseline sample time (0) and T n is the time point of the post-ingestion 
sample in minutes. 
2. The DOBs will be tran sformed into percentag e dose reco very rates (PDRs) at a 
specific time point (n) by [CONTACT_21734]: 
PDR n =1.817853*DOB n × w0.5378 × h0.3963 
While: w = weight (in kg), h = height (in cm) 
64
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20624] 30: 
 
6.2.5 Child-Turcotte-Pugh Score 
The Child-Turcotte-Pugh score provides an as sessment of the prognosis of chronic liver 
disease. In this classification sy stem, various laboratory and clin ical parameters are scored as 
shown in Table 6-1 . 
Table 6-1 Child-Turcotte-Pugh Scoring System 
Categories  Scoring System  
Bilirubin +1: <2 mg/dL 
+2: 2-3 mg/dL 
+3: >3 mg/dL 
Albumin +1: >3.5 g/dL 
+2: 2.8-3.5 g/dL 
+3: <2.8 g/dL 
International normalized ratio +1: <1.7 
+2: 1.7-2.2 
+3: >2.2 
Ascites +1: No ascites 
+2: Ascites, medically controlled +3: Ascites, poorly controlled 
Encephalopathy +1: No encephalopathy 
+2: Encephalopathy, medically controlled 
+3: Encephalopathy, poorly controlled 
 
The total score determines the classification as show in Table 6-2 . 
Table 6-2 Child-Turcotte-Pugh Classification 
Points Class One-Year Survival Two-Year Survival 
5-6 A 100% 85% 
7-9 B 81% 57% 
10-15 C 45% 35% 
 
65
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20625]  Class A, well-compensated cirrhosis with a 
nearly 100% one-year survival. Additionally, a 2- point increase in the actual score will be 
used as an indication of  progression of disease. 
6.2.6 MELD Score 
The MELD score assesses the severity of chr onic liver disease and is used for prioritizing 
allocation of liver transplants. The MELD score will be calculated from laboratory tests 
(serum bilirubin, serum creatinine, and prothrombin time INR).  
MELD score = (0.957 × ln(serum creatinine) + 0.378 × ln(serum bilirubin) + 1.120 × ln(INR) 
+ 0.643) × 10 (if hemodialysis, value for creatinine is automatically set to 4.0) 
Note: If any score is less than 1, the MELD assumes the score is equal to 1.  
6.2.7 EGD Evaluation  
Subjects will undergo an EGD within 2 months  prior to randomization and within 14 to 28 
days after the final 26th dose of IMP or where feasible following study termination and the 
following information will be collected.  
Esophageal varices, if present, will be classified as follows:  
1. Large varices >50% impi[INVESTIGATOR_21680];  
2. Small varices <25% impi[INVESTIGATOR_21681];  
3. Medium varices are intermediate between small and large varices.  
Subjects with medium or large varices or varices with red signs, regardless of size, will be 
excluded from study participation. Red signs in clude red wale marki ngs (dilated venules 
oriented longitudinally on the variceal surface),  cherry red spots (small, red, spotty dilated 
venules usually about 2 mm in diameter on the va riceal surface) or hematocystic spots (large, 
round, crimson red projection greater than 3 mm that looks like a blood blister on the variceal 
surface). Subjects without varices or with small varices will advance to HVPG measurement 
and liver biopsy. Consistent with the American Association for the Study of Liver Disease 
practice guidelines ( Garcia-Tsao 2007), subjects with small vari ces will not receive treatment 
66
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20626] 4 weeks prior to 
randomization. 
6.3 Exploratory Assessments 
6.3.1 Chronic Liver Disease Questionnaire 
The CLDQ is a tool used to measure health-related quality of life in subjects with liver 
disease and has demonstrated good reliability an d validity in subjects  with chronic liver 
disease (Younossi 1999). The instrument includes 29 questions with 6 domains: abdominal symptoms, systemic symptoms, fatigue, activ ity, emotional function, and worry. The CLDQ 
will be given to the subject at the beginning of the visit ( Table 12-2 ), and will be considered 
source documentation. The CLDQ is provided in Section 12.3 . 
6.3.2 Biomarkers 
Blood will be collected for assessment of biomarkers ( Table 12-2 ). Tests will include the ELF 
test, FibroTest (FibroSure), and galectin-3. At each of these times, a blood sample will be frozen (–20°C; –4°F) and held before treatment and at the end of treat ment for other possible 
poststudy biomarker testing. 
[IP_ADDRESS]  Enhanced Liver Fibrosis Test 
The ELF is a method to predict the severity a nd clinical outcome in chronic liver diseases. 
The ELF test uses a routine blood sa mple to measure procollagen-III 
aminoterminal-propeptide, tissue inhibitor of  matrix metalloproteinase-1, and hyaluronic 
acid. 
[IP_ADDRESS]  FibroTest/FibroSure 
The FibroTest score (FibroSure in the [LOCATION_002]), is a composite score that has been correlated with the extent of liver fibrosis. Th is score is calculated from the subject’s age, 
67
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 67 sex, alpha-2-macroglobulin, haptoglobin, apolipoprotein A1, γ-glutamyl transpeptidase, and 
total bilirubin. 
[IP_ADDRESS]  Galectin-3 
Blood will be collected for assessment of galectin-3 (Table 12-2 ). 
6.3.3 Plasma and Serum Samples  
Plasma and serum samples will be collected at Visits 1, 13, and 26 ( Table 12-2) . These 
samples will be stored at at –20°C. 
6.[ADDRESS_20627] 1 infusion of study tr eatment will be evaluated for 
safety. Safety assessments will include incidence of AEs during study treatment, emergent 
physical examination abnormalities, emergent vital sign and ECG abnormalities, and 
laboratory parameter abnormalities.  
6.4.1 Vital Sign Measurements 
Vital sign measurements (inc luding heart and respi[INVESTIGATOR_697], blood pressure, and body 
temperature) will be collected before administration of IMP ( Table 12-1  and Table 12-2 ).  
Blood pressure will be obtained with the subj ect in the supi[INVESTIGATOR_21682] a 1-minute interval be tween measurements. The average of the 
2 measurements will be recorded. 
6.4.2 Physical Examination 
A complete physical examination, including he ight and weight, will be performed at 
screening, with particular atte ntion to examination for stigma ta of liver disease/cirrhosis 
(Table 12-1 ). A limited physical examination will only include weight and examination of the 
heart, lung, and abdomen dur ing the treatment phase ( Table 12-2 ).  
68
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20628] 12-lead ECG will be performed during screening and the treatment phase ( Table  
12-1 and Table 12-2 ).  
Twelve-lead ECGs will be systematically digitally  recorded after the subject has been in the 
supi[INVESTIGATOR_21683] [ADDRESS_20629] radiographs (posterior-ant erior and lateral views) will be performed at screening ( Table  
12-1). 
6.4.5 Adverse Events 
[IP_ADDRESS]  Definitions of Adverse Events 
The investigator is responsi ble for reporting all treatment-e mergent AEs (TEAEs) that are 
observed or reported during the st udy, regardless of their relations hip to IMP or their clinical 
significance. 
An AE is defined as any untoward medical occu rrence in a subject enrolled into this study, 
regardless of its causal relationship to IMP. Subjects will be instructed to contact [CONTACT_21735]. 
A TEAE is defined as any event not present before exposure to IMP or any event already 
present that worsens in either intensity or frequency after exposure to IMP. An SAE is defined as any event that results in  death, is immediately li fe threatening, requires 
inpatient hospi[INVESTIGATOR_1081], results in persistent or 
significant disability/incapacity, or is a congenital anomaly/birth defect. Important medical 
events that may not result in death, be life threat ening, or require hospi[INVESTIGATOR_21684], based upon appropriate medical judgment, they may jeopardize the 
subject or may require medical or surgical in tervention to prevent one of the outcomes listed 
in this definition. Examples of such medical events include allergic bronchospasm requiring 
69
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 69 intensive treatment in an emergency room or  at home, blood dyscrasias or convulsions that 
do not result in inpatient hos pi[INVESTIGATOR_059], or the development of drug dependency or drug 
abuse. 
[IP_ADDRESS]  Eliciting and Documenting Adverse Events 
All AEs (serious and nonserious) will be assess ed beginning at screening and up to [ADDRESS_20630] been 
hospi[INVESTIGATOR_057], had any accidents, used any new medications, or changed concomitant 
medication regimens (both prescripti on and over-the-counter medications). 
In addition to subject observations, AEs identif ied from any study data (eg, laboratory values, 
physical examination findings, ECG changes) or identified from  review of other documents 
that are relevant to subject safety will be documented on the AE page in the eCRF. 
[IP_ADDRESS]  Reporting Adverse Events 
All AEs reported or observed during the study will be recorded on the AE page in the eCRF. 
Information to be collected includes drug tr eatment, dose, event term, time of onset, 
investigator-specified assessment of severity a nd relationship to IMP, time of resolution of 
the event, seriousness, any required treatment or evaluations, and outcome. Adverse events 
resulting from concurrent illnesses, reactions to  concurrent illnesses, reactions to concurrent 
medications, or progression of disease states mu st also be reported. All AEs will be followed 
to adequate resolution. The Medical Dicti onary for Regulatory Activities (MedDRA, 
Version 17.1) will be used to code all AEs.  
Any medical condition that is present at the ti me that the subject is  screened but does not 
deteriorate should not be reported as an AE. However, if the subject’s condition deteriorates 
at any time during the study, it should be recorded as an AE. 
70
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 70 Any AE that meets SAE criteria ( Section [IP_ADDRESS]) must be reported to the sponsor (designee) 
immediately (ie, within 24 hours) after the time study center personnel first learn about the 
event.  
Study center personnel should complete the AE  eCRF using electronic data capture, 
designating the event as serious. If electronic data capture is unavailable, complete an SAE 
form using the following contact [CONTACT_3031]: 
 Pharmacovigilance 
 [ADDRESS_20631] 
 Wilmington, NC [ZIP_CODE] 
 SAE Hotline: [PHONE_342] 
 SAE Fax line:  [PHONE_343] 
[IP_ADDRESS]  Assessment of Severity 
The severity, or intensity, of an AE refers to the extent to which an AE affects the subject’s 
daily activities. The intensity of the AE will be rated as mild, moderate, or severe using the 
following criteria: 
Mild: These events require minimal or no tr eatment and do not interfere with the 
subject’s daily activities. 
Moderate: These events result in a low level of  inconvenience or concern with the 
therapeutic measures. Moderate events  may cause some interference with 
normal functioning. 
Severe: These events interrupt a subject’s usual daily activity and may require systemic 
drug therapy or other treatment. Severe  events are usually incapacitating. 
 
Changes in the severity of an AE should be documented to allow an assessment of the 
duration of the event at each le vel of intensity to be performe d. Adverse events characterized 
as intermittent do not require documentation of onset and duration of each epi[INVESTIGATOR_1865]. 
[IP_ADDRESS]  Assessment of Causality 
The investigator’s assessment of an AE’s relationship to IMP will be part of the documentation process, but it is not  a factor in determining what is or is not reported in the 
71
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20632] artic le in causing or contributing to the AE will be 
characterized using the followi ng classification and criteria: 
Unrelated: This relationship suggests that there is no association between the IMP and the 
reported event. 
Possible: This relationship suggests that treatmen t with the IMP caused or contributed to 
the AE, ie, the event follows a reasonable  temporal sequence from the time of 
IMP administration or follows a known re sponse pattern to the IMP, but could 
also have been produced by [CONTACT_1604]. 
Probable: This relationship suggests that a reas onable temporal sequence of the event 
with IMP administration exists a nd, based upon the known pharmacological 
action of the drug, known or previously re ported adverse reactions to the drug 
or class of drugs, or judgment based on the investigator’s clinical experience, 
the association of the event with the IM P seems likely. The event disappears or 
decreases on cessation or reduction of the dose of IMP. 
Definite: This relationship suggests that a definite  causal relationship exists between IMP 
administration and the AE, and other conditions (concurrent illness, progression/expression of disease state, or concurrent medi cation reaction) do 
not appear to explain the event. The event reappears or worsens if the IMP is 
re-administered. 
[IP_ADDRESS]  Exceptions 
While the following events may fulfill the serious criteria, they do not need to be reported as 
SAEs: hospi[INVESTIGATOR_602]/emergency room stays lasting less than 24 hours not meeting other 
serious criteria, hospi[INVESTIGATOR_21685], hospi[INVESTIGATOR_21686], and events expected as pa rt of progression of disease under study.  
[IP_ADDRESS]  Follow-Up of Subjects Reporting Adverse Events 
All AEs must be reported in detail on the appropriate page in the eCRF and followed to 
satisfactory resolution, until the investigator deem s the event to be chronic or not clinically 
significant, or until the subject is considered to be stable. 
72
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20633] be followed up to determine outcome (including spontaneous miscarriage, 
elective termination, normal birth, or congenital abnormality) and status of mother and child, 
even if the subject was discontinued from th e study. Pregnancy complications and elective 
terminations for medical reasons must be reported as an AE or SAE. Spontaneous 
miscarriages must be reported as an SAE. 
Pregnancy must be reported in the same manne r as an SAE to [COMPANY_003] Pharmacovigilance by [CONTACT_21736] [ADDRESS_20634] be discontinued immediately (or pe r sponsor directive), and the 
pregnancy report form submitted to [COMPANY_003] Pharm acovigilance via the SAE fax line. The study 
center should submit the pregnancy follow-up form to document th e outcome of the 
pregnancy (health of the neonate). In the even t of a miscarriage, therapeutic abortion, death 
in utero, or the pregnancy outcome leads to an SAE for the mother, follow the Procedure for 
Reporting an SAE ( Section [IP_ADDRESS] ). In the event of a congenita l anomaly, an SAE form for 
the baby [CONTACT_21737].  
Any SAE occurring in association with a pregna ncy that is brought to the investigator’s 
attention after the subject has completed the study and considered by [CONTACT_21738]. 
6.4.[ADDRESS_20635] (hematology, clinical chemistry,  or urinalysis) or other safety 
assessment results (eg, ECGs, radiological scans, vital sign measurements), including those 
that worsen from baseline, believed to be clinically significant in the medical and scientific judgment of the investig ator are to be recorded as AEs or SAEs. 
However, any clinically significant laboratory assessments that are associated with the 
underlying disease, unless judged by [CONTACT_21739]’s condition, are not to be  reported as AEs or SAEs. 
73
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 73 6.4.8 Hematology 
Tests will include the following: 
Hemoglobin  Differential: 
Hematocrit   Neutrophils 
Red blood cells   Lymphocytes 
White blood cells  Monocytes 
Red cell indices  Basophils 
Platelet count  Eosinophils 
  Prothrombin time 
  Partial thromboplastin time 
  Haptoglobin 
6.4.9 Blood Chemistry 
Tests will include the following:  
Alanine aminotransferase  Chloride Phosphorus 
Albumin Creatinine Potassium 
Alkaline phosphatase Fasting insulin level Sodium 
Aspartate aminotransferase  γ-glutamyl transferase  Total and direct bilirubin 
Bicarbonate Glucose Total protein 
Blood urea nitrogen  Lactate dehydrogenase  Uric acid 
Calcium Magnesium  
6.4.10  Urinalysis 
Refer to the Study Manual for collecting urinalysis  samples. Tests will include the following: 
Color Glucose Red blood cells 
Clarity Blood Hyaline and other casts 
pH Bilirubin Bacteria 
Specific gravity Leukocyte esterase Epi[INVESTIGATOR_21687] 
6.4.11  Alcohol TLFB 
Current alcohol consumption will be assessed during the treatment phase ( Table 12-2 ) using 
the Alcohol TLFB. The Alcohol TLFB is a drinking assessment method that obtains estimates 
of daily drinking and has been evaluated with clinical and nonclinical  populations. Using a 
74
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20636] at the beginning of the visit 
(Table 12-2 ), and will be considered source documentation. 
Subjects should be instructed to refrain from regular alcohol use duri ng the study. If subjects 
are found on the calendar to be drinking greater than or equal to [ADDRESS_20637] alcoholic drinks per week, they will be asked to stop drinki ng or reduce their intake. The Alcohol TLBF 
Calendars for the years 2015, 2016, and 2017 alo ng with instructions are provided in 
Section 12.4 .  
6.5 Pharmacokinetic Assessments 
Plasma levels of GR-MD-02 will be assessed in all subjects ( Table 12-2 ). Plasma levels of 
GR-MD-[ADDRESS_20638] (DSMB) meeting, the panel will evaluate GR-MD-[ADDRESS_20639]’s eCRF. Each label will state the 
study number, subject number, matrix (plasma), and study day of the sample. 
6.[ADDRESS_20640] blood draw n for hematology and chemistry (including 
fasting insulin level). Refer to the Study Manua l for instructions for sample handling and 
shippi[INVESTIGATOR_007]. 
75
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 75 7 Statistical and Analytical Plan 
A summary of statistical methods is presented in the following sections and will be described 
in more detail in the statistical analysis plan (SAP). 
7.1 Primary Efficacy Endpoint 
The primary efficacy endpoint analysis is the baseline-adjusted change in HVPG at 1 year 
(53-55 weeks) in subjects treated with placebo as compared to subjects treated with 
GR-MD-02 (2 mg/kg/week or 8 mg/kg/week). 
7.2 Secondary Efficacy Endpoints 
The secondary endpoints are: 
• The baseline-adjusted absolute change in  the CPA at 1 year as determined by 
[CONTACT_21740] 
• The baseline-adjusted change in liver stiffness as determined by [CONTACT_21741], at Infusion Visit 13, and 14-28 days after final infusion 
• The baseline-adjusted change in the metabolic capacity of the liver as 
determined by [CONTACT_21742]
30 of the MBT (if available) at  screening, Infusion Visit 13, 
and 14-28 days after final infusion 
• The difference between GR-MD-02-treate d and placebo-treated subjects in the 
progression of cirrhosis at 1 year, defined as the development of any of the 
following:  
o esophageal variceal hemorrhage or  portal hypertensive gastropathy 
hemorrhage (confirmed by [CONTACT_21700]) 
o clinically apparent ascites 
o spontaneous bacterial peritonitis 
o overt hepatic encephalopathy 
76
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 76 o an increase in Child-Turcotte-Pugh score ≥[ADDRESS_20641] without prior varices 
o progression from small to medium or large varices 
o qualification for liver transplant defined as a MELD score ≥15 
o listing for a liver transplant or the performance of a liver transplant 
o liver-related mortality 
7.3 Exploratory Endpoints 
Exploratory endpoints are to evaluate: 
• Difference in health-related quality of life (using the subject -completed CLDQ) 
following administration of GR-M D-02 or placebo at 1 year  
• Baseline-adjusted change in FibroTest (FibroSure) and ELF score at Infusion 
Visits 7, 13, 20, and 14-28 days after final infusion 
• Changes in liver biopsy staining for al pha smooth muscle and galectin-3 in 
subjects treated with GR-MD-02 or placebo at 1 year 
o HVPG ≥10 and <15 mm Hg (elevated por tal pressure, with potential 
development of varices, clas sified as clinically signi ficant portal hypertension)  
o HVPG ≥15 (increased incidence of co mplications from varices) 
7.4 Safety Endpoints 
The safety endpoints include the incidence of AEs during study treatment, emergent physical 
examination abnormalities, emergent vital sign and ECG abnormalities, and laboratory 
parameter abnormalities.  
77
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 77 7.5 Pharmacokinetic Endpoint 
The PK endpoints include plasma concentr ations and population PK parameters of 
GR-MD-02.  
7.6 Sample Size Calculations 
A total of approximately 156 subjects will be en rolled in the study. Sample size calculations 
are based on the comparison of the primary efficacy variable, change in HVPG from 
baseline, with the following assumptions (k ey assumptions discussed as follows):  
1. True mean change in HVPG from baseline at 52 weeks in the placebo group, 
Δp= 0 
2. True mean change in HVPG from baselin e at 52 weeks in either GR-MD-02 dose 
group, ΔG = -2 mm Hg 
3. Common SD for difference in HVPG, σ = 3 mm Hg 
4. Null hypothesis, H 0: θ = G - Δp= 0 
5. Type I error, α = 0.05 (2-sided significance test) 
6. Power = 80% 
7. Statistical test = 2-sample  t -test for mean difference 
8. Randomization ratio = 1:1:1 
9. Drop-out rate of 25% 
For a mean difference of 2 mm Hg and accoun ting for a 25% dropout rate, the total sample 
size of 156 subjects (n = 52 subjects per group)  will be required to achieve power of 80% 
with a 2-sided type I error rate of 0.05. 
78
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 78 Discussion of assumptions: 
1. True mean change in HVPG from baselin e at [ADDRESS_20642] 20% from 
baseline, the risk of variceal bleeding,  rebleeding, and othe r complications of 
portal hypertension such as ascites, s pontaneous bacterial peritonitis and 
hepatorenal syndrome markedly d ecreases and survival improves 
(Villanueva Villanueva 2009; Escorsell 2000; Abraldes  2003). In addition, a 10% 
reduction in HVPG has been shown to prevent the development of varices 
(Groszmann  2005). Therefore, it appears that  a reduction in HVPG between 10% 
to 20% confers clinical benefit of reduced variceal bleeding. It is anticipated that 
the mean HVPG for the experimental groups will be between 10 mm Hg and 
15 mm Hg, as in other si milarly designed studies (Groszmann  2005). Therefore, a 
2 mm Hg change in HVPG between placebo and treated groups would be between 
15% and 20%, which is likely to be of clinical significance.  
3. The common SD for difference in HVPG over 1 year for subjects in the placebo 
group was set at σ = 3 mm Hg. This assumption was determined from primary 
data, obtained from the investigator ([CONTACT_21776]-Tsao), from a 
longitudinal clinical study ( Groszmann  2005). Table 7-1  and Table 7-2  show data 
for subjects in the placebo group who had baseline and 12-month HVPG measurements (n = 82), of which 32 s ubjects had a baseli ne HVPG <10 mm Hg 
and 50 subjects had a baseline HVPG ≥10 mm Hg. From these data, the SD of the 
absolute change at 12 months in th e placebo group was 2.85 mm Hg. Therefore, 
the assumption of 3 mm Hg for the samp le size calculation appears valid.  
79
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 79 Table 7-1 HVPG (mm Hg) at Baseline and 12 Months for Subjects in the 
Placebo Group in the Timolol Clinical Study 
Treatment Variable N Mean SD Median Lower 
Quartile Upper 
Quartile Min Max 
Placebo HVPG 
Baseline 82 11.29 3.97 10.75 8 14 6 23.5 
Placebo HVPG 
12 mo 82 10.98 3.82 10.9 8 14 4 22.0 
Abbreviations: Max, maximum; min, minimum; SD, standard deviation 
Source: Groszmann 2005  
Table 7-2 Absolute Change in HVPG  (mm Hg) at 12 Months for Subjects in 
the Placebo Group in the Timolol Clinical Study  
Treatment N Mean SD Median Lower 
Quartile Upper 
Quartile 
Placebo 82 0.31 2.85 0.5 -1 2 
Abbreviation: SD, standard deviation Source: Groszmann 2005  
 
7.7 Analysis Sets 
The following analysis sets will be used in the statistical analyses. 
Full-Analysis set (FAS): The FAS, or intent-t o-treat group, will consis t of all subjects who 
were randomly assigned to IMP. All analyses using the FAS will group subjects according to 
randomized treatment. The FAS will be used  as the primary efficacy analysis set. 
Modified-Intent-to-Treat analysis  set: The modified intent-to-treat set will consist of all 
subjects who were randomly assigned, rece ived at least [ADDRESS_20643] 
1 postbaseline efficacy assessment (from Section 6.2). All analyses using the modified 
intent-to-treat set will group subjects according to randomized treatment. 
Per-protocol set: The per-protocol set will cons ist of all FAS subjects who have at least 80% 
compliance with study treatment, have not taken any prohibited medication, have no 
significant protocol deviations, and restricted to each subject’s time on IMP plus 30 days 
thereafter for the analysis of progression of  efficacy events. All analyses using the 
per-protocol set will group subjects according to treatment actually received. 
80
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 80 Safety set: The safety set will consist of all subjects who received any IMP. All analyses 
using the safety set will group subjects ac cording to treatment actually received. 
Pharmacokinetic set: The PK analysis set will  consist of subjects w ho provide at least 1 C max 
PK sample. 
7.8 Description of Subgroups to Be Analyzed 
No subgroup analyses are planned. 
7.9 Statistical Analysis Methodology 
Statistical analysis will be performed using SAS software Version 9.1.3 or later. Continuous 
variables will be summarized by [CONTACT_21743], the SD, 
median, 25th and 75th percentiles, minimum value, and maximum value. Point estimates and 
the associated 95% confidence interval for the difference in baseline-adjusted efficacy 
parameters will be summarized in a simila r manner. Categorical variables will be 
summarized by [CONTACT_21744]. All 
baseline and postbaseline data used for safety and efficacy evaluations will be listed in data 
listings. 
Baseline is defined as the last assessment pr ior to infusion with IMP (ie, the predosing 
assessment present in the database that is most  proximate to the time of IMP administration). 
Measurements that are obtained after the firs t dose of study treatment will be considered 
postbaseline values. Change from baseline is defined as the postbaseline value minus the 
baseline value. 
All statistical tests will be 2-sided and will be  at the 5% level of significance. Due to the 
small number of subjects expected to be en rolled at each study center, all summaries and 
analyses will be performed using data pooled across study centers. Any imbalances in subject 
enrollment at study centers will be reviewed  and methods for accommodating/eliminating the 
potential effect on efficacy analyses  will be addressed in the SAP. 
For analysis variables that are not normally distributed, alternative methods will be applied including the use of the Poiss on-regression model (or the negative binomial) for counts data. 
81
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 81 For others, a nonparametric method based on Hodge-Lehmann estimate (or similar) and 
associated 95% confidence interval on median difference will be applied ( Hodges  1963). 
Methods for dealing with missing data including da tes, efficacy and safety results will be 
specified in the SAP.  
Details of the statistical analyses, methods, ad justments for multiplicity, and data conventions 
will be described in the SAP. 
7.9.1 Analysis of Primary Efficacy Endpoint 
The primary efficacy endpoint analysis is the baseline-adjusted change in HVPG at 1 year 
(53 to 55 weeks) in subjects treated with pl acebo as compared to subjects treated with 
GR-MD-02 (2 mg/kg/week or 8 mg/kg/week). Change in HVPG from baseline will be 
compared between treatments groups using anal ysis of covariance adjusted for baseline 
HVPG. Treatment group will be included in the m odel as indicator variables where T1 = [ADDRESS_20644] is randomly assigned to 2 mg/kg/week and 0 otherwise and T2 = [ADDRESS_20645] is 
randomly assigned to 8 mg/kg/week and 0 ot herwise. The following hypotheses will be 
tested based on the parameter estim ates (and standard errors) from  the fit of the analysis of 
covariance model: 
H01: Δ T1 - Δp= 0 vs HA1: ΔT1 - Δp ≠ 0 
H02: Δ T2 - Δp= 0 vs HA2: ΔT2 - Δp ≠ 0 
The closed testing procedure of Bonferroni-Holm ( 1988) will be used to adjust for multiple 
comparisons of each GR-MD-02 dose (T1 and T2) with placebo so that overall type I error 
rate is preserved at 0.050  (2-sided). If at least 1 of 2 doses is found to be significantly better 
than placebo, the 2 doses will be compared with each other at the 0.05 level to address dose 
response. 
7.9.2 Analysis of Key Secondary Efficacy Endpoints 
Key secondary endpoints will be examined using a gatekeeper statistic al approach. If the 
primary endpoint is significant ( α <0.05), analysis will proceed to the secondary endpoints. 
Since the evaluation of secondary endpoints wi ll proceed using a prespecified hierarchy 
without statistical correction fo r multiplicity, if a secondary e ndpoint does not meet statistical 
82
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 82 significance, all subsequent analysis will be treated as exploratory only. The key secondary 
endpoints will be evaluated in the following sequence:  
• Baseline-adjusted mean change in CPA will be compared between treatment groups using robust regression (M estimation method, Huber  1973) to account 
for skewedness of the data with adjustment for baseline CPA.  
• The baseline-adjusted mean change in Fi broScan at 1 year will be analyzed 
using similar methods previously defi ned for the primary efficacy endpoint  
• The baseline-adjusted mean change in MB T (if available) at 1 year will be 
analyzed using similar methods previously defined for the primary efficacy endpoint  
• The incidence of complications of cirr hosis with portal hypertension at [ADDRESS_20646] 1 infusion of study tr eatment will be evaluated for 
safety. The safety analyses will include evaluation of the incidence of treatment-emergent adverse events (TEAEs), grade 3 or greater AE s, SAEs and AEs leading to discontinuation of 
study treatment using the Common Terminology Criteria for Adverse Events Version 4.0 or higher. Laboratory and vital sign measurement will be evaluated over time on study using 
descriptive statistics. Shift analyses of rele vant clinical laborator y parameters will be 
produced showing shifts  across low, normal, and high categories. 
All heart rate (beats per mi nute), 12-lead ECG parameters, PR interval (milliseconds), QRS 
interval (milliseconds), QT interval (millisec onds), and QTc interval (milliseconds) will be 
measured, and overall interpretation will be  summarized for all subjects by [CONTACT_21745].  
83
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 83 Electrocardiogram parameters will be summarized using descriptive statistics. Mean and 
mean change from baseline values will be presented for every scheduled assessment. Change 
from baseline will be calculated as the pos tbaseline measurement minus the baseline 
measurement. If either the baseline or postb aseline value is missing, the observation will not 
be included in the change from baseline su mmary. In addition, count s and percentages for 
ECG overall interpretation (normal, abnormal, clinically significant,  and not clinically 
significant) will be presented for each scheduled assessment. 
For physical examinations, the results (normal,  abnormal, or not done) by [CONTACT_21746]-up visits will be summarized 
with descriptive statistics by [CONTACT_21747] d visit. For physical examinations performed 
at postrandomization time points, the number and percentage of  subjects with no change or 
any significant changes since the previous examination will be presented by [CONTACT_21748]. In addition, a shift table will be in cluded to summarize the number and percentage 
of subjects with changes from baseline to e ach postrandomization visit by [CONTACT_21749]. The number and percentage of subjects with normal and abnormal 
results (clinically significant versus not clinic ally significant) for each body system will be 
presented by [CONTACT_1570]. 
Vital sign measurements (respi[INVESTIGATOR_1516], heart rate , temperature, systolic  and diastolic blood 
pressure), height (at screening only), and BMI will be summarized descriptively at each 
scheduled visit. Mean and mean change from baseline values will be presented. Change from 
baseline will be calculated as postbaseline m easurement minus baseline measurement. If 
either the baseline or postbaseline value is missing, the observation will not be included in the change from baseline summary. 
All safety data will be listed by [CONTACT_1130], parameter, and time point. 
7.9.5 Pharmacokinetic Analyses 
Pharmacokinetic data will be summarized descriptively. Descriptive statistics for GR-MD-02 
concentrations by [CONTACT_21750], SD, coefficient of 
variation, minimum, median, maximum, geom etric mean and coefficient of variation 
geometric mean as appropriate. If appropriate, da ta will be further stra tified by [CONTACT_654], gender, 
and/or other demographic variables. Standard graphics, including plots of arithmetic mean 
(+SD) concentration by [CONTACT_21751] (bot h linear and semi-logarithmic), overlay plots 
84
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 84 of mean concentration and individual concentr ations (both linear and semi-logarithmic) will 
be provided. 
All concentrations below the limit of quantifica tion or missing data will be labelled as such 
in concentration data listings . Concentrations below the lowe r limit of quantitation will be 
treated as zero in summary statistics of concentration data. All PK concentration data will be 
listed by [CONTACT_3598]. 
No statistical analyses o f the phar macokinetic  data are planned. GR-MD-02 plasma levels 
will be used to evaluate system ic exposure following multiple dosing. Based on  the high  
correlation between area under the concentration-time curve and C max of GR-MD-02 in the 
Phase 1 clinical study ( Galectin  2014), the plasm a levels  at 2 hours (approximate C max) 
following the dose of GR-MD-[ADDRESS_20647] modeling 
approach will be used to evaluate the population pharmacokinetics of GR-MD-02. The 
population pharmacokinetic modeling will be pe rformed using the NONMEM software (Icon 
Development Solutions, Hanover, MD). 
The structural PK model will contain PK parameters such as clearance and volume of 
distribution as fixed-effect parameters. The inte rsubject variability in the parameter estimates 
and the random residual error in the data will be estimated with  an appropriate error model. 
The best-fit model will be selected based on the standard criteria, such as objective function 
values and diagnostic plots. Covariates affecti ng the intersubject variability will be explored 
and, if possible, quantified. Pharmacokinetic da ta from the previous Phase [ADDRESS_20648] 
85
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 85 infusion of study treatment, will be summarized by [CONTACT_21752] (WHO Drug 
Dictionary (Version 1 Sep 2014). Medications that  started prior to the first infusion of study 
treatment but continued during treatment w ill also be defined as concomitant. Ongoing 
medications without stop date s are considered concomitant. Prior medications, defined as 
nonstudy medications with a stop date before the first infusion of study treatment, will also be summarized by [CONTACT_1570]. Medications with partial onset/stop dates that indicate 
that the medication could be concomitant in rela tion to the start date of study treatment will 
be classified as concomitant. Otherwise, they  will be classified as  prior medications.  
Investigational medicinal produc t exposure and overall percent compliance will be calculated 
per subject in the FAS population and summa rized by [CONTACT_21753]. 
Additional exploratory analys es for the MBT (if available):  A model/algorithm will be 
developed to increase correlation with HVPG measurements and biopsy results. 
All available breath test parameters (DOB at the respective times) will be collected from the 
completed eCRFs. The DOBs will be transfor med to PDR by [CONTACT_21754] (see Section 6.2.4 ). The area under the DOB and under the PDR 
curve will be calculated for a 5-minute time interval resulting in cDOB and cPDR at 5, 10, 
15, 20, 25, 30, 35, 40, 45, 50, 55, and [ADDRESS_20649] demographic 
and laboratory data. Using a cut-point on the scor e, a binary diagnosis of (yes/no) will be 
obtained for several HVPG cut-offs, as well as histological scores. Cr oss-validation methods 
will be used to test algorithm stability. 
7.9.7 Interim Analyses 
An interim analysis of PK data will be c onducted for the DSMB meeting as outlined in 
Section 10.1.1: Independent Data Safety Monitoring Board. 
86
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 86 7.10 Data Quality Assurance 
The sponsor’s (or an authorized representa tive’s) Quality Assurance Department may 
conduct on-site audits of all aspects of the clinical  study either during the study or after the 
study has been completed. 
The clinical study may also be subject to in spection by [CONTACT_21755] (national or 
foreign), as well as the institutional review board/independent ethics committee (IRB/IEC) to 
ascertain that the study is being or has b een conducted in accordance with protocol 
requirements, Good Clinical Practice (GCP), as well as the applicable regulatory 
requirements. 
7.10.[ADDRESS_20650] be reviewe d, signed, and dated by [CONTACT_9916] a 
timely manner. The completed eCRF will be collected by [CONTACT_21756]. 
Clinical data management will be performed  in accordance with applicable Galectin 
Therapeutics Inc standards and data cleaning pro cedures to ensure the integrity of the data, 
87
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 87 eg, removing errors and inconsistencies in the data. Adverse events and concomitant 
medication terms will be coded using MedDRA, an  internal validated medication dictionary. 
After database lock, each study center will re ceive a CDROM containing all of their study 
center-specific eCRF data as entered into  Medidata RA VE for the study, including full 
discrepancy and audit history. Additionally, a CDROM copy of all of the study center’s data 
will be created and sent to the sponsor for storage. A duplicate CDROM copy will be 
maintained by [CONTACT_21757]. In all cases, subject initials will  not be collected or 
transmitted to the sponsor. 
88
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20651] 
Federal regulations and the International Conference on Ha rmonisation (ICH) harmonised 
tripartite guideline E6(R1): Good Clinical Practice require that approval be obtained from an 
IRB/IEC before participation of human subjects  in research studies.  Before study onset, the 
protocol, informed consent, advertisements to be used for the recruitment of study subjects, 
and any other written information regarding this  study to be provided to the subject or the 
subject’s legal guardian must be approved by [CONTACT_1201]/IEC. Documentation of all IRB/IEC 
approvals and of the IRB/IEC compliance with ICH E6(R1): GCP will be maintained by [CONTACT_21758]. 
All IRB/IEC approvals should be signed by [CONTACT_3433] e IRB/IEC chairman or designee and must 
identify the IRB/IEC name [CONTACT_3816], the clin ical protocol by [CONTACT_21759], and the date approval or a favorable opi[INVESTIGATOR_11744]. 
The investigator is responsibl e for providing written summaries of the progress and status of 
the study at intervals not exceeding 1 year or  otherwise specified by [CONTACT_1201]/IEC. The 
investigator must promptly supply the sponsor or its designee, the IRB/IEC, and, where 
applicable, the institution, with written reports  on any changes significantly affecting the 
conduct of the study or increas ing the risk to subjects. 
8.[ADDRESS_20652] their origin in 
the Declaration of Helsinki, ICH E6(R1) GCP, and all applicable regulations. 
8.[ADDRESS_20653] Information and Consent 
A written informed consent in compliance with US Title 21 Code of Federal Regulations 
(CFR) Part [ADDRESS_20654]. An informed consent 
template may be provided by [CONTACT_21760]. If any 
institution-specific modificati ons to study-related procedures  are proposed or made by [CONTACT_21761], the consent should be  reviewed by [CONTACT_21762] 
89
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 89 IRB/IEC submission. Once reviewed, the consent will be submitted by [CONTACT_21763]/IEC for review and approval before the start of the study. If the ICF is revised 
during the course of the study, all active participa ting subjects must sign the revised form. 
Before recruitment and enrollment, each prospective subject or his or her legal guardian will 
be given a full explanation of the study and be allowed to read the approved ICF. Once the 
investigator is assured that  the subject/legal guardian understands th e implications of 
participating in the study, the subject/legal guardian will be asked to give consent to 
participate in the study by [CONTACT_12568]. 
The investigator shall retain the signed original ICF(s) and give a copy of the signed and 
dated ICF to the subject or legal guardian. 
90
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 90 9 Investigator’s Obligations 
The following administrative items are meant to guide the investigator in the conduct of the 
study but may be subject to change based on in dustry and governmental standard operating 
procedures, working practice documents, or guidelines. Changes will be reported to the 
IRB/IEC but will not result in protocol amendments. 
9.[ADDRESS_20655] (or the subject’s lega l guardian), except as necessary for monitoring 
and auditing by [CONTACT_456], its designee, the US FDA, or the IRB/IEC. 
The investigator and all employees and coworker s involved with this study may not disclose 
or use for any purpose other than performan ce of the study any data, record, or other 
unpublished, confidential information disclosed to those individuals for the purpose of the 
study. Prior written agreement fr om the sponsor or its design ee must be obtained for the 
disclosure of any said confidentia l information to other parties. 
9.[ADDRESS_20656]’s disease. 
91
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 91 9.3 Investigator Documentation 
Prior to beginning the study, the investigator w ill be asked to comply with ICH E6(R1) 8.2 
and 21 CFR 50 by [CONTACT_21764] l documents, including but not limited to: 
• IRB/IEC approval 
• Original investigator-signed investigat or agreement page of the protocol 
• Form FDA 1572, fully executed, and all updates on a new fully executed Form 
FDA 1572 
• Curriculum vitae for the investigator and each subinvestigator listed on Form 
FDA 1572 
• Financial disclosure information to allow the sponsor to submit complete and 
accurate certification or disclosure statements required under [ADDRESS_20657] provide  to the sponsor a commitment to 
promptly update this information if any relevant changes occur during the course of the investigation and for 1 y ear after the completion of the study. 
• IRB/IEC-approved informed consent, samples of study center advertisements for recruitment for this study, and any ot her written information regarding this 
study that is to be provided to  the subject or legal guardian 
9.[ADDRESS_20658] 
The investigator agrees that the study will be conducted according to the principles of ICH 
E6(R1). The investigator will conduct all aspe cts of this study in accordance with all 
national, state, and local laws or regulations. Study information from this protocol will be 
posted on publicly available clinicaltrials.gov before enrollment of subjects begins. 
9.[ADDRESS_20659] the study as outlined in this protocol and in accordance 
with ICH E6(R1) and all applicab le guidelines and regulations. 
92
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 92 9.6 Adverse Events and Study Report Requirements 
By [CONTACT_4907], the investigator agrees to subm it reports of SAEs according to 
the timeline and method outlined in this protoc ol. In addition, the investigator agrees to 
submit annual reports to the study ce nter IRB/IEC, as appropriate. 
9.7 Investigator’s Final Report 
Upon completion of the study, the investigator, where app licable, should inform the 
institution; the investigator/in stitution should provide the I RB/IEC with a summary of the 
study’s outcome and the sponsor and regulatory authority(ies) with any reports required. 
9.[ADDRESS_20660] approval of a 
marketing application in an ICH E6(R1) region and until there are no pending or 
contemplated marketing applications in an IC H E6(R1) region or at  least [ADDRESS_20661] 
elapsed since the formal discontinuation of clinical development of the IMP. These 
documents should be retained for a longer pe riod, however, if required by [CONTACT_21765]. It is the responsibility of the sponsor to inform the investigator/institution as to when these documents no longer need to 
be retained. 
9.9 Publications 
After completion of the study, the data may be  considered for reporting at a scientific 
meeting or for publication in a scientific journal. In these cases, the sponsor will be 
responsible for these activities and will work with the investigators to determine how the 
manuscript is written and edited, the number and order of authors, the publication to which it 
will be submitted, and other related issues. The sponsor has final approval authority over all 
such issues. 
Data are the property of the sponsor and ca nnot be published without  prior authorization 
from the sponsor, but data and publica tion thereof will not be unduly withheld. 
93
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20662] 
received 7 doses of IMP. The purpose of this earl y look at safety is to ensure that there are no 
unexpected AEs in the population being evaluated in this study. The second scheduled DSMB review meeting will occur after approximately 50% of the total number of subjects to 
be enrolled has received 13 doses of IMP. The DSMB will then meet again after 50% of 
subjects have received [ADDRESS_20663] 30 subjects. There should be approximately 
10 subjects who received 2 mg/kg and 10 subjects who received 8 mg/kg in this group of 
subjects. With the aid of a clinical pharmacologist on the panel, the DSMB will assess C max 
levels as a surrogate for systemic exposure, with increasing number of doses in the groups 
receiving IMP and compare the levels to the safety margins indicated by [CONTACT_7419]-term animal 
toxicology studies. 
The investigative study center staff, subject s, the sponsor and its representatives, and 
representatives of the CRO, except those res ponsible for providing unblinded data to the 
DSMB, will remain blinded throughout the full duration of the study until after the database 
is locked at the conclusion of  the blinded treatment period. 
94
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20664] operating procedures. For the purposes of this study, a blinded and unblinded monitoring team will be used. 
10.1.3  Inspection of Records 
Investigators and institutions involved in the study will permit study-related monitoring, 
audits, IRB/IEC review, and regulatory inspec tions by [CONTACT_21766]. In the event of an audit, the investig ator agrees to allow th e sponsor, representatives 
of the sponsor, or a regulatory agency (eg, FD A or other regulatory agency) access to all 
study records. 
The investigator should promp tly notify the sponsor and [COMPANY_003] of any audits scheduled by [CONTACT_21767] c opi[INVESTIGATOR_21688]. 
10.[ADDRESS_20665] be submitted in writing to the investigator’s 
IRB/IEC for approval before subjects can be enrolled into an amended protocol. 
95
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20666]’s source 
documentation any deviation from the approved protocol. The investigator may implement a 
deviation from, or a change of, the protocol to eliminate an immediate hazard to study 
subjects without prior IRB/IEC approval. As so on as possible after such an occurrence, the 
implemented deviation or change, the reasons for it, and any proposed protocol amendments 
should be submitted to the IRB/IEC for review and approval, to the sponsor for agreement, 
and to the regulatory aut horities, if required. 
A deviation from the protocol is an unin tended or unanticipated departure from the 
procedures or processes approved by [CONTACT_941] s ponsor and the IRB/IEC and agreed to by [CONTACT_1275]. A significant deviation occurs when there is nonadherence to the protocol by [CONTACT_21768] a significant, additi onal risk to the subject. Significant 
deviations can include nonadherence to inclus ion or exclusion criteria, enrollment of the 
subject without prior sponsor approval, or nonadherence to FD A regulations or ICH E6(R1) 
GCP guidelines, and will lead to the subject being withdrawn from the study ( Section 4.2 ). 
Protocol deviations wi ll be documented by [CONTACT_11782]. Principal i nvestigators will be notified in writing by [CONTACT_21769]. The IRB/IEC should be notified of all protocol deviations in a timely manner. 
10.[ADDRESS_20667] visit 
(includes follow-up visit). 
10.4 Final Report 
Whether the study is completed or prematurely terminated, the sponsor will ensure that the 
clinical study reports are prepar ed and provided to the regulato ry agency(ies), as required by 
[CONTACT_8146](s). The sp onsor will also ensure that the clinical study 
96
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 96 reports in marketing applications meet the standards of the ICH E6(R1): Structure and 
content of clinical study reports. 
Where required by [CONTACT_21770], an investigator signatory will be 
identified for the approval of the clinical study report. The investigator will be provided 
reasonable access to statistical tables, figures , and relevant reports and will have the 
opportunity to review the complete study results. Upon completion of the clinical study report, the sponsor will provide the investigator with 
the full summary of the study results. The invest igator is encouraged to share the summary 
results with the study subjects, as appropriate. The study results  will be posted on publicly 
available clinical trial registers. 
97
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20668] 
Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological 
treatment of portal hyperten sion and long-term prognosis of cirrhosis. Hepatology. 
2003;37(4):902-8. 
Babor TF, Higgins-Biddle JC, Saunders JB, et al. AUDIT; The alcohol use disorders 
identification test: guidelines for use in prim ary care, 2nd ed. [Internet].  Geneva: World 
Health Organization; 2000 [cited 2013 Apr 30]. p. 17. Available from: 
http://www.who.int/substance_abuse/activities/sbi/en/ . 
Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. Dig Dis. 
2010;28(1):162-8. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic 
fatty liver disease: practice Guideline by [CONTACT_21771], American College of Gastroenterology, and the American Gastroenterological 
Association. Hepato logy. 2012;55(6):2005-23. 
Di LS, Sundblad V , Cerliani JP , et al. When galectins recogn ize glycans: from biochemistry 
to physiology and back again. Biochemistry. 2011;50(37):7842-57. 
Escorsell A, Bordas JM, Castañeda B, et al. Pr edictive value of the variceal pressure response 
to continued pharmacological therapy in pati ents with cirrhosis and portal hypertension. 
Hepatology. 2000;31(5):1061-7. Exalenz Bioscience Ltd. Clin ical study of the BreathID
® system to train the algorithm for the 
¹³C-octanoate breath test with  or without the ¹³C-methacetin  breath test (OBT and MBT, 
respectively) for correlation with  histological findings of non- alcoholic fatty liver disease 
(NAFLD). January 2015. IDE Approval G140254. 
Exalenz Bioscience Ltd. Clin ical study of the BreathID® LF system to train the algorithm for 
the ¹³C-methacetin breath test (MBT) in assessm ent of portal hypertension in patients with 
compensated liver cirrhosis. November 2014. IDE Approval G140190. Exalenz Bioscience Ltd. Pi[INVESTIGATOR_21689]
® 
system for detection of cirrhosis using the¹³C -methacetin breath test (MBT). July 2008. IDE 
Approval G080107. Galectin Pharmaceuticals Inc (Norcross, Ge orgia). A multi-center, partially blinded, 
maximum tolerated multiple dose escalation, Phase 1 clinical trial to evaluate the safety of 
GR-MD-02 in subjects with non-alcoholic stea tohepatitis (NASH) with advanced hepatic 
fibrosis. 17 Jun 2014. Protocol No.: GT-020. Version 4. 96 p. 
98
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 98 Garcia-Tsao G, Sanyal AJ, Grace ND. Prevention and management of gastroesophageal 
varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46(3):922-38. 
Garcia-Tsao G, Bosch J. Management of va rices and variceal hemorrhage in cirrhosis. N 
Engl J Med. 2010;362(9):823-32. 
Groszmann RJ, Garcia-Tsao G, Bosch J, et al . Beta-blockers to prevent gastroesophageal 
varices in patients with cirrhosis . N Engl J Med. 2005;353(21):2254-61. 
Hodges, JL and Lehmann EL. Estimates of location based on rank te st. The Annals of 
Mathematical Statis tics. 1963;34(2):598-611. 
Huber, PJ. Robust Regression: Asymptotics, Conjectures and Monte Carlo. Annals of 
Statistics. 1973;1:799-821. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin 
Pharmacokinet. 2005;44(10):1051-65. 
McHutchison J, Goodman Z, Patel K, et al. Farg litazar lacks antifibrotic activity in patients 
with chronic hepatitis C infecti on. Gastroenterology . 2010;138(4):1365-73. 
Rinella ME. Will the increased prevalence of non alcoholic steatohepatitis (NASH) in the age 
of better hepatitis C virus therapy make  NASH the deadlier disease? Hepatology. 
2011;54(4):1118-20. Sobell LC, Maisto SA, Sobell MB, et al. Relia bility of alcohol abusers’ self-reports of 
drinking behavior. Behav Res Ther. 1979;17(2):157-60. 
Sobell LC, Sobell MB. Timeline Follow-back: A technique for assessing self-reported 
alcohol consumption. In: Litten RZ, Allen JP (editors). Measuring alcohol consumption: 
Psychosocial and biochemical methods . Humana; -Totowa, NJ: 1992. P. 41-72. 
Sobell LC and Sobell MB. Alcohol Timeline Fo llowback (TLFB) Users’ Manual. Toronto: 
Addiction Research Foundation, 1995. Traber PG, Zomer E. Therapy of experimental NASH and fibrosis with galectin inhibitors. 
PLoS One. 2013a;8(12):e83481. Traber PG, Chou H, Zomer E, et al. Regression of fibrosis and re versal of cirrhosis in rats by 
[CONTACT_21772]-induced  liver disease. PLoS One. 2013b;8(10):e75361. 
Villanueva C, Aracil C, Colomo A, et al. Ac ute hemodynamic response to beta-blockers and 
prediction of long-term outcome in primary prophylaxis of variceal bleeding. 
Gastroenterology. 2009;137(1):119-28. 
99
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 99 Younossi Z, Guyatt G, Kiwi M, et al. Developm ent of a disease specif ic questionnaire to 
measure health related quality of life in patients with chronic liver disease. Gut. 
1999;45(2):295-300. 
Williams CD, Stengel J, Asike MI, et al. Prev alence of nonalcoholic fatty liver disease and 
nonalcoholic steatohepatitis among a largely mi ddle-aged population utilizing ultrasound and 
liver biopsy: a prospective study. Gastroenterolog y. 2011;140(1):124-31. 
Wong VW, Vergniol J, Wong GL,  et al. Diagnosis of fibros is and cirrhosis using liver 
stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51(2):454-62. 
 
100
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 100 12 Appendices 
12.1 Appendix: Schedule of Events  
 
101
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 101 Table 12-1 Schedule of Events - Prescreening and Screening 
Procedure Prescreening Screening  
Week Week –9 Week -8 to Day 0a 
IWRS X X 
Informed consent X  
NASH Diagnosis Xb  
FibroScan Xb  
Inclusion/exclusion criteria  X 
AUDIT  X 
Demographic information  X 
Medical, surgical, medication history  X 
12-lead ECG  X 
Hematology  Xc 
Blood chemistry  Xd 
Coagulation profile  X 
MELD score  X 
Viral hepatitis B and C serology  X 
HIV serology  X 
Urine drug screen (amphetamines, cocaine, and nonprescription opi[INVESTIGATOR_858])  X 
Urinalysis  Xe 
Serum pregnancy test (females of childbearing potential only)  Xf 
Chest radiographs (posterior-anterior and lateral views)  X 
Child-Turcotte-Pugh score  X 
Complete physical examination  Xg 
 
102
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 102 Table 12-1 Schedule of Events - Pr escreening and Screening, Continued  
Procedure Prescreening Screening  
Week Week –9 Week -8 to Day 0a 
Vital sign measurements  Xh 
MBT (if available)  Xi 
EGD  Xj 
HVPG  Xk 
Liver biopsy  X 
AE monitoring  X 
Abbreviations: AE, adverse event; AUDIT, Al cohol Use Disorders Identification Test;  ECG, electrocardiogram; EGD, es ophagogastroduodenoscopy; HIV, human 
immunodeficiency virus; HVPG, hepa tic venous pressure gradient; IWRS , interactive web response system; MBT, 13C-methacetin breath test;  MELD, model for end-stage 
liver disease; NASH, nonalc oholic steatohepatitis. 
a The screening visit window is up to [ADDRESS_20669] had a previous liver biopsy with either advanced bridging fibrosis (Ishak stage 4) or cirrhosis (Ishak stage  5 or 6) are eligible to move forward to screening. 
Subjects with a presumptive clinic al diagnosis of NASH (based on the assessment of  the principal investigator) will have a Fibr oScan to assess the potential for fibrosis. 
Subjects who have a FibroScan score of ≥12.[ADDRESS_20670] adva nced fibrosis and will proc eed to screening. Likewise, subjects with a documented 
qualifying FibroScan score within the previous 12 months of screening may proceed to screening. 
c Hematology will include complete blood cell count with differential (red blood cells, white blood cells, red cell indices, platelets, hemoglobin, and hematocrit). 
d Blood chemistry will incl ude alanine aminotransferase, as partate aminotransferase, albumin , alkaline phosphatase, bicarbonate,  blood urea nitrogen,  calcium, chloride, 
creatinine, glucose, lactate dehydrogenase , magnesium, phosphorus, potassium , sodium, total and direct bilirubin, total protein , uric acid, γ-glutamyl transferase, and fasting 
insulin level. Subjects mu st be in a fasted state prior to blood collection. 
e Urinalysis will include bacter ia, bilirubin, blood, crystals, color, clarity, epi[INVESTIGATOR_1663], glucose, hyaline and other cas ts, leukocyte esterase, nitrite,  pH, specific gravity, 
ketones, protein, red blood cells , white blood cells, and yeast. 
f Serum pregnancy test for females of chil dbearing potential only. (A urine pregnancy te st will be given every 4 weeks during th e treatment phase.) 
g Including height (in cm) and weight (in kg) with particular attention to examination for stigmata of liver disease/cirrhosis). 
h Vital sign measurements include heart and respi[INVESTIGATOR_697], blood pressure, and body temperature. Blood pressure will be obtained with the subject in the supi[INVESTIGATOR_21690] a 1-minute interval between m easurements. The average of the 2 measurements will be recorded.  
i The MBT  (if available)  will be performed prior to EGD, HVPG, or liver biopsy (at the discretion of the investigator). The study center will make a follow-up telephone call 
to the subject to capture any AEs that may have  occurred within [ADDRESS_20671] had an EGD within 2 months prior to randomization. S ubjects with medium or large varices or varices with red signs (red wale marks or red spots), 
regardless of size, will be excluded from study participation. Subjects without varices or with small varices will continue to HVPG measurement and liver biopsy. 
103
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20672] bot h an HVPG measurement ≥6 mm Hg and a liver biopsy with advanced bridging fibrosis (Ishak stage 4) or cirrhosis (Ishak stage 5 or 6), presumably 
due to NASH. Subjects without varices or with small varices will have  hepatic venous catheterization with measurement of both w edged and free hepatic venous pressures 
and standardized calcul ation of the HVPG prior to randomiz ation and first IMP infusion.  
 
104
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 104 Table 12-2 Schedule of Events - Randomization, Tr eatment Phase, and Follow-up/Early Termination 
Infusion Visit 0 1 2, 3, 4, 5, 
6 7 8, 9, 10, 
11, 12 13 14, 15, 16, 17, 
18, 19 20  21 22, 23, 24, 
25 26 14-28 Days 
After Final 
Dose 14 Days After 
Previous Visit/ET 
Week ± 3 days  1 3, 5, 7, 9, 
11 13 15, 17, 19, 
21, 23 25 27, 29, 31, 33, 
35, 37 39 41 43, 45, 47, 
49 51 53-55 57 
IWRS R
A
N
D
O
M
I 
Z
A
T 
I 
O
N X X X X X X X X X X X X 
FibroScan Xa    X      X  
MBT (if available)     X      X  
CLDQb X         X   
Alcohol TLFB b X X - Inf 
Visit 5  X - Inf 
Visit 9 X X - Inf Visit 
17  X X - Inf Visit 
25    
Limited physical 
examinationc X X X X X X X X X X X X 
Urine pregnancy testd  X - 
Inf Visits 
3, 5 X X -  
Inf Visits 
9, 11 X X - 
Inf Visits  
15, 17, 19  X X -  
Inf Visits  
23, 25    
Vital sign measurementse X X X X X X X X X X X X 
Hematologyf  X  X  X  X   X X  
Blood chemistryg X  X  X  X   X X  
MELD score     X     X   
Biomarkers blood sampleh X    X      X  
Plasma and serum sample 
for storage X    X     X   
IMP administrationi X X X X X X X X X X   
12-lead ECG     X       X 
Child-Turcotte-Pugh score     X     X   
EGDj            X  
HVPGj           X  
 
105
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 105 Table 12-2 Schedule of Events - Randomization, Treatment  Phase, and Follow-up/Early Termination, Continued  
Infusion Visit 0 1 2, 3, 4, 5, 
6 7 8, 9, 10, 
11, 12 13 14, 15, 16, 17, 
18, 19 20  21 22, 23, 24, 
25 26 14-28 Days 
After Final 
Dose 14 Days After 
Previous Visit/ET 
Week ± 3 days  1 3, 5, 7, 9, 
11 13 15, 17, 19, 
21, 23 25 27, 29, 31, 33, 
35, 37 39 41 43, 45, 47, 
49 51 53-55 57 
Liver biopsyj 
           X  
Assessment of cirrhosis 
complications  X - Inf 
Visits  
3, 5 X X - Inf 
Visits  
9, 11 X X - Inf Visits 
15, 17, 19  X X - Inf 
Visits  
23, 25 X   
AE monitoring X X X X X X X X X X X X 
Concomitant medications X X X X X X X X X X X X 
PK samplek X X -  
Inf Visits 
2, 3, 4 X X - Inf 
Visit 10 X     X   
Abbreviations: AE, adverse event; TLFB, Timeline Followback; EGD, esophagogastroduodenoscopy; CLDQ, chronic liver disease quest ionnaire; 
ECG, electrocardiogram; ET, early terminati on; HVPG, hepatic venous pressure gradient; IMP, investigational medicinal product; Inf, infusion; IWRS, 
interactive web response system; MBT, 13C-methacetin breath test;  MELD, model for end-stage liver disease; PK, pharmacokinetic. 
Note: Subjects will be entered into the study and randomly assi gned to IMP if they have both an HVPG screening measurement ≥6 mm Hg and a liver biopsy 
with advanced bridging fibrosis (Ishak stage 4) or cirrhosis (Ishak stage 5 or 6) presumably due to NASH.  
Note: Acceptable treatment windows for infu sions will be ± 3 days. Infu sions given outside of accept ed windows will be consider ed “out-of-window” doses. If a 
dose is out of window, the subject should be brought back into compliance with their visit dosing schedule. The subject should not dose within 7 days of the 
previous or next dose unless the medical monitor is consulted. 
Note: Randomization must occur prior to Infusion Visit 1. 
a Within [ADDRESS_20673] in the supi[INVESTIGATOR_21691] a 1-minute interval between measurements . The average of the 
2 measurements will be recorded. 
106
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 106 f Hematology will include complete blood cell count with differential (red blood cells, white blood cells, , red cell indices, platelets, hemoglobin, and 
hematocrit). 
g Blood chemistry will include alanine aminotransferase, aspartat e aminotransferase, albumin, alka line phosphatase, bicarbonate,  blood urea nitrogen, calcium, 
chloride, creatinine, glucose, lactate dehydrogenase, magnesium, phosphorus, potassium, sodium, total and direct bilirubin, tot al protein, uric acid, 
γ-glutamyl transferase, and fasting insu lin level. Subjects must be in a fasted state prior to blood collection. 
h Biomarker blood tests will include the enhanced liver fibrosis test, FibroTest (FibroSure), and galectin-[ADDRESS_20674] infusion and at Infusion 
Visits 13 and 14 to 28 days following final 26th infusion. 
i IMP administration will occur after the following procedures: limi ted physical examination, vital sign measurements, hematolog y, blood chemistry, and 
biomarker blood samples. 
j Within [ADDRESS_20675] be performed on a differ ent day within the 14- to 28-day follow-up period than when the HVPG assessment is pe rformed. 
k The PK sample will be collected 2 hours after the end of the IMP infusion. 
 
107
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-[ADDRESS_20676] undergoes a liver transplant. 
c Complications of chronic liver disease in clude ascites, spontaneous bacterial peritonitis, variceal bleeding, and encephalopat hy. 
 
108
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 108 12.2 Appendix: The AUDIT Questionnaire 
The full AUDIT manual will be provided in the Study Manual. 
Babor TF, Higgins-Biddle JC, Saunders JB, et al. AUDIT; The alcohol use disorders 
identification test: guidelines for use in prim ary care, 2nd ed. [Internet].  Geneva: World 
Health Organization; 2000 [cited 2013 Apr 30]. p. 31. Available from: 
http://www.who.int/substance_abuse/activities/sbi/en/ . 
[ADDRESS_20677]: Self-Report Version 
PATIENT: Because alcohol use can affect your health and can interfere with certain medications and 
treatments, it is important that we ask some questions about your use of alcohol . Your answers 
will remain confidential so please be honest. 
Place an X in one box that best describes your answer to each question . 
Questions [ADDRESS_20678] Never Monthly 2-4 times 2-3 times 4 or more 
a drink containing alcohol? or less a month a week times a week 
2. How many drinks containing 1or2 3or4 5or6 [ADDRESS_20679] on a typi[INVESTIGATOR_21692]? 
3. How often do you have six or Never Less than Monthly Weekly Daily or 
more drinks on one monthly almost 
occasion? daily 
4. How often during the last Never Less than Monthly Weekly Daily or 
year have you found that you monthly almost 
were not able to stop drinking daily 
once you had started? 
5. How often during the last Never Less than Monthly Weekly Daily or 
year have you failed to do monthly almost 
what was normally expected of daily 
you because of drinking? 
6. How often during the last year Never Less than Monthly Weekly Daily or 
have you needed a first drink monthly almost 
in the morning to get yourself daily 
going after a heavy drinking 
session? 
7. How often during the last year Never Less than Monthly Weekly Daily or 
have you had a feeling of guilt monthly almost 
or remorse after drinking? daily 
8. How often during the last year Never Less than Monthly Weekly Daily or 
have you been unable to remem- monthly almost 
ber what happened the night daily 
before because of your drinking? 
9. Have you or someone else No Yes, but Yes, 
been injured because of not in the during the 
your drinking? last year last year 
10. Has a relative, friend, doctor, or No Yes, but Yes, 
other health care worker been not in the during the 
concerned about your drinking last year last year 
or suggested you cut down? 
Total 
110
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 109  
12.3 Appendix: The Chronic Live r Disease Questionnaire 
 
111
 Younossi 1997 
Revised December 28, 1998  The Chronic Liver Disease Questionnaire (CLDQ) 
 
This questionnaire is designed to find out how you have been feeling during the last two weeks.  You will 
be asked about your symptoms related to your liver disease, how you have been affected in doing 
activities, and how your mood has been.  Please complete all of the questions  and select only one 
response for each question.  
 
1. How much of the time during the last two weeks have you been troubled by a feeling of 
abdominal bloating?  
 
[ADDRESS_20680] two weeks?  
 
[ADDRESS_20681] you experienced bodily pain? 
 [ADDRESS_20682] you felt sleepy during the day?  
 
[ADDRESS_20683] of the time 
3 A good bit of the time 
4 Some of the time 
5 A little of the time 
6 Hardly any of the time 7 None of the time 
 
 
  
 
 
112
 Younossi [ADDRESS_20684] you experienced abdominal pain?  
 
[ADDRESS_20685] two weeks has shortness of breath been a problem for 
you in your daily activities? 
 
[ADDRESS_20686] you not been able to eat as much as 
you would like ? 
 
[ADDRESS_20687] you been bothered by [CONTACT_21773]?  
 
[ADDRESS_20688] you had trouble lifting or carrying heavy objects?  
 [ADDRESS_20689] of the time 
3 A good bit of the time 
4 Some of the time 
5 A little of the time 6 Hardly any of the time 
7 None of the time 
 
 
113
 Younossi [ADDRESS_20690] you felt anxious?  
 [ADDRESS_20691] you felt a decreased level of  energy? 
 [ADDRESS_20692] you felt unhappy?  
 [ADDRESS_20693] you felt drowsy?  
 
[ADDRESS_20694] you been bothered by a limitation of 
your diet?  
 [ADDRESS_20695] of the time 
3 A good bit of the time 
4 Some of the time 
5 A little of the time 
6 Hardly any of the time 7 None of the time 
 
 
 
114
 Younossi [ADDRESS_20696] you been irritable?  
 [ADDRESS_20697] you had difficulty sleepi[INVESTIGATOR_21693]?  
 
[ADDRESS_20698] you been troubled by a feeling of 
abdominal discomfort?  
 
[ADDRESS_20699] 
your liver disease has on your family? 
 
[ADDRESS_20700] you had mood swings?  
 
[ADDRESS_20701] of the time 
3 A good bit of the time 
4 Some of the time 5 A little of the time 
6 Hardly any of the time 
7 None of the time 
 
115
 Younossi [ADDRESS_20702] you been unable to fall asleep at 
night?  
 
[ADDRESS_20703] you had muscle cramps?  
 
[ADDRESS_20704] you been worried that your 
symptoms will develop into major problems?  
 
[ADDRESS_20705] you had a dry mouth?  
 
[ADDRESS_20706] you felt depressed ? 
 
[ADDRESS_20707] of the time 
3 A good bit of the time 
4 Some of the time 5 A little of the time 
6 Hardly any of the time 
7 None of the time 
 
116
 Younossi [ADDRESS_20708] you been worried about your 
condition getting worse?  
 
[ADDRESS_20709] you had problems concentrating?  
 
[ADDRESS_20710] two weeks?  
 [ADDRESS_20711] you been worried about never feeling 
any better ? 
 
[ADDRESS_20712] you been concerned about the 
availability of a liver if you need a liver transplant?  
 
[ADDRESS_20713] of the time 
3 A good bit of the time 4 Some of the time 
5 A little of the time 
6 Hardly any of the time 
7 None of the time
 
117
 Younossi 1997 
Révisée 28 décembre 1998  Questionnaire sur la maladie chronique du foie  
(Chronic Liver Disease Questionnaire, CLDQ) 
 
 Ce questionnaire est conçu pour comprendre comment vous vous êtes senti au cours des deux 
dernières semaines.  On vous posera des questions concernant des symptôm es associés à votre maladie 
du foie, concernant comment vous avez été affecté dans vos activités, et comment votre humeur s'en est 
vue changer.  Veuillez compléter toutes les questions  et ne sélectionner qu'une seule  réponse pour 
chaque question.  
 
1. Au cours des deux dernières semaines, pendant combien de temps vous êtes-vous senti 
affecté par un ventre gonf l
é? 
 
1 Tout le temps 
2 La plupart du temps 
3 Une bonne partie du temps 
4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps  2. Pendant combien de temps vous êtes-vous senti fatigué au cours des deux  dernières 
semaines?  
 1 Tout l e 
temps 
2 La plupart du temps 
3 Une bonne partie du temps 
4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
 
3. Au cours des 2 dernières semaines, pendant combien de temps avez-vous ressenti une 
douleur physique? 
 
1 Tout le temp s
 
2 La plupart du temps 
3 Une bonne partie du temps 
4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
 
4. Au cours des deux dernières semaines, pendant combien de temps vous êtes-vous senti 
fatigué pendant la journé e? 
 1
 Tout le temps 
2 La plupart du temps 3 Une bonne partie du temps 4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
118
 Younossi 1997 
Révisée 28 décembre 1998  5. Au cours des deux dernières semaines, pendant combien de temps avez-vous ressenti une 
douleur abdominale?  
 
[ADDRESS_20714] pendant vos activités quotidiennes? 
 
1 Tout le temp s
 
2 La plupart du temps 3 Une bonne partie du temps 
4 Une partie du temps 5 Quelque peu pendant cette période 
6 À pei ne 
7 En aucun temps  
7. Au cours des deux dernières s
emaines, n'avez-vous pas été en mesure de manger autant 
que vous l'auriez souhaité ? 
 
1 Tout  
le temps 
2 La plupart du temps 3 Une bonne partie du temps 
4 Une partie du temps 
5 Quelque peu pendant cette période 6 À peine 
7 En aucun temps 
 8. Au cours des deux premières semaines, pendant combien de temps avez-vous été affecté par un manque de puissance phy sique
? 
 1 Tout le temps 2 La plupart du temps 
3 Une bonne partie du temps 
4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
 
9. Au cours des 2 dernières semaines, à quelle fréquence avez-vous rencontré des difficultés 
pour transporter des objets lou rds
? 
 1 Tout le temps 
2 La plupart du temps 3 Une bonne partie du temps 
4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
119
 Younossi 1997 
Révisée 28 décembre 1998  10. Au cours des deux dernières semaines, pendant combien de temps vous êtes-vous senti 
anxieux pendant la journée? 
 
1 Tou t
 le temps 
2 La plupart du temps 3 Une bonne partie du temps 4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
 
11. Au cours des 2 dernières semaines, à quelle fréquence vous êtes-vous senti comme étant 
affecté par une diminution du
 niveau d'énergie? 
 
1 Tout le temps 
2 La plupart du temps 
3 Une bonne partie du temps 
4 Une partie du temps 5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
 
12. Pendant combien de temps vous êtes-vous senti malheureux au cours des deux  dernières 
semaines?  
 
1 Tout le t
emps 
2 La plupart du temps 3 Une bonne partie du temps 
4 Une partie du temps 
5 Quelque peu pendant cette période 6 À peine 
7 En aucun temps 
 
13. Au cours des deux dernières semaines, pendant combien de temps vous êtes-vous senti 
somnolent au cours de la journée ?
 
 1 Tout le temps 2 La plupart du temps 
3 Une bonne partie du temps 
4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
 
14. Au cours des deux  dernières semaines, à quelle f
 réquence avez-vous été empêché par une 
limite de votre diète?  
 
1 Tout le temps 
2 La plupart du temps 3 Une bonne partie du temps 
4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
120
 Younossi 1997 
Révisée 28 décembre 1998   
15. Au cours des deux dernières semaines, pendant combien de temps vous êtes-vous senti 
irritable au cours de l
a journée?  
 
1 Tout le temps 
2 La plupart du temps 3 Une bonne partie du temps 
4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
 
16. Au cours des deux dernières semaines, pendant combien de temps avez-vous eu de la 
difficulté à dormir pendant  
la nuit?  
 
1 Tout le temps 
2 La plupart du temps 
3 Une bonne partie du temps 4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
 17.  Au cours des deux dernières semaines, pendant combien de temps vous êtes-vous senti affligé d'un inconfort a bd
ominal?  
 
1 Tout le temps 
2 La plupart du temps 
3 Une bonne partie du temps 
4 Une partie du temps 5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
 
18. Au cours des deux dernières semaines, à quel point avez-vous été inquiet de l'impact de la 
maladie sur votre famille? 
 
1 
Tout le temps 
2 La plupart du temps 3 Une bonne partie du temps 
4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
 
121
 Younossi 1997 
Révisée 28 décembre 1998  19. Pendant combien de temps vous êtes-vous senti malheureux au cours des deux  dernières 
semaines? Avez-vou s r
éussi à amener un marbre qui donne du charme à cet endroit vide d e 
la maison.  
 
1 Tout le temps 
2 La plupart du temps 3 Une bonne partie du temps 
4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
 
20. Au cours des deux dernières semaines, pendant combien de temps avez-vous été incapable 
de dormir pendant la n 
uit? 
 
1 Tout le temps 
2 La plupart du temps 
3 Une bonne partie du temps 4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
 21. Au cours des deux dernières semaines, à quelle f réqu
 ence avez-vous eu des crampes 
musculaires?  
 
1 Tout le temps 
2 La plupart du temps 
3 Une bonne partie du temps 
4 Une partie du temps 5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
 
22.  Au cours des deux dernières semaines, combien de temps avez-vous été inquiété de voir 
vos symptômes se développer en  
problèmes majeurs?  
 
1 Tout le temps 
2 La plupart du temps 
3 Une bonne partie du temps 
4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
 23. Pendant combien de temps avez-vous senti que votre gorge était sèche?  
 
[ADDRESS_20715]
upart du temps 
3 Une bonne partie du temps 
4 Une par tie du temps 
5 Quelq ue
 peu pendant cette période 
6 À peine 
7 En aucun temps 
122
 Younossi 1997 
Révisée 28 décembre 1998  24. Au cours des deux dernières semaines, pendant combien de temps vous êtes-vous senti 
déprimé ? 
 
1 Tout le temps 
2 
La plupart du temps 
3 Une bonne partie du temps 
4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
 
25. Au cours des deux dernières semaines, à quel intervalle vous êtes-vous inquiété de voir 
votre situation empi[INVESTIGATOR_21694]?  
 
1 T
out le temps 
2 La plupart du temps 3 Une bonne partie du temps  
4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
 
26. Pendant combien de temps avez-vous senti que vous aviez des problèmes de 
concentration? 
 
1 Tout l e 
temps 
2 La plupart du temps 3 Une bonne partie du temps 
4 Une partie du temps 
5 Quelque peu pendant cette période 6 À peine 
7 En aucun temps 
 
27. Au cours des deux dernières semaines, pendant combien de temps vous êtes-vous senti 
importuné par des démangeaisons?  
 1 
Tout le temps 
2 La plupart du temps 
3 Une bonne partie du temps 
4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
 
28. Au cours des deux dernières semaines, vous êtes-vous inquiété de ne jamais vous sentir 
mieux qu'à ce moment ? 
 1 Tout  
le temps 
2 La plupart du temps 
3 Une bonne partie du temps 
4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps 
123
 Younossi 1997 
Révisée 28 décembre 1998   
29. Au cours des deux dernières semaines, pendant combien de temps vous êtes-vous inquiété 
de recevoir une transplantati on
 dont vous aviez besoin?  
 
1 Tout le temps 
2 La plupart du temps 3 Une bonne partie du temps 
4 Une partie du temps 
5 Quelque peu pendant cette période 
6 À peine 
7 En aucun temps
 
124
 Younossi 1997  
Revisado el 28 de diciembre de 1998  Cuestionario sobre la enfermedad hepática crónica (CLDQ, por su sigla en 
inglés)  
 
 Este cuestionario está diseñado para averiguar cómo se ha sentido durante las últimas dos semanas. Se 
le harán preguntas sobre los síntomas que ha sufrido a causa de su enfermedad hepática, sobre cómo se 
han visto afectadas sus actividades cotidianas y sobre su estado de ánimo. Complete todas las preguntas
  
y seleccione sólo una respuesta para cada pregunta.  
1. Durante las últimas dos semanas ¿con qué frecuencia ha sufrido molestias a causa de una 
sensación de distensión abdominal?  
 1 Siempre  
2 La mayor parte del tiemp 
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 2. D
urante las últi
mas do
s semanas ¿con qué frecuencia se ha sentido cansado o fatigado?  
 1 Siempre  
2 La mayor parte 
del tiemp
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 
3. Durante las últimas dos semanas ¿con qué frecuencia ha sentido dolor corporal?  
 1 Siempre  
2 La mayor parte del tiem 
po 
3 U
na buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 4. D
urante las últi
mas do
s semanas ¿con qué frecuencia se ha sentido somnoliento durante el 
día? 
 1 Siempre  
2 La mayor parte
 del tiemp
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
  
 
125
 Younossi 1997  
Revisado el 28 de diciembre de 1998   
 
 
5. Durante las últimas dos semanas ¿con qué frecuencia ha sentido dolor abdominal?  
 1 Siempre  
2 La mayor parte 
del tiemp
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 
6. D
urante las últi
mas do
s semanas ¿con qué frecuencia la falta de aliento le ha dificultado la 
realización de sus actividades coti
dianas?  
 
1 Siempre  
2 La mayor parte del tiemp
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 
7. D
urante las últi
mas 
dos semanas ¿con qué frecuencia no ha podido comer todo lo que 
hubiera querido?  
 1 Siempre  
2 La mayor 
parte del tiemp
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 
8. D
urante l as últim
as dos 
semanas ¿con qué fr ecuencia ha sufrido molestias a causa de una 
sensación de debilidad? 
 
1 Siempre  
2 La mayor parte del tiemp
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 9. D
urante las últi
mas do
s semanas ¿con qué frecuencia ha tenido inconvenientes al levantar 
o transportar objetos pesados? 
 1 S
iempre  
2 La mayor parte del tiemp
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
126
 Younossi 1997  
Revisado el 28 de diciembre de 1998  6 Casi nunca  
7 Nunca  
 
 
 
10. Durante las últimas dos semanas ¿con qué frecuencia se ha sentido ansioso?  
 
1 Siempre  
2 La mayor parte 
del tiemp
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 
11. D
urante las últi
mas do
s semanas ¿con qué frecuencia se ha sentido débil?  
 
1 Siempre  
2 L a mayor parte
 del ti
empo 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 
12. D
urante las últi
mas do
s semanas ¿con qué frecuencia se ha sentido triste?  
 
1 Siempre  
2 La mayor parte 
del tiemp
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 13. D
urante las últi
mas do
s semanas ¿con qué frecuencia se ha sentido somnoliento?  
 1 Siempre  
2 La mayor parte 
del tiemp
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 
14. D
urante las últi
mas do
s semanas ¿con qué frecuencia se ha sentido molesto  a causa de una 
limitación en su dieta?  
 
1 Siempre  
2 La mayor parte del tiemp
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
127
 Younossi 1997  
Revisado el 28 de diciembre de 1998  7 Nunca  
 
  
 
 15. Durante las últimas dos semanas ¿con qué frecuencia ha estado irritable?  
 1 Siempre  
2 La mayor parte 
del tiemp
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 16. D
urante las últi
mas do
s semanas ¿con qué frecuencia ha tenido dificultad para dormir por 
la noche?  
 
1 Siempre  
2 La mayor parte
 del tiemp
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 
17. 
 Durante las úl
timas 
dos semanas ¿con qué frecuencia ha sufrido molestias a causa de  una 
sensación de malestar abdomina
l? 
 
1 Siempre  
2 La mayor parte del tiemp
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 
18. D
urante las últi
mas do
s semanas ¿con qué frecuencia ha estado preocupado por la 
repercusión que tiene su enfermedad 
hepática en su familia?  
 
1 Siempre  
2 La mayor parte del tiemp
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 
19. D
urante las últi
mas do
s semanas ¿con qué frecuencia ha sufrido cambios bruscos de 
ánimo?  
 
1 Siempre  
2 La mayor par
te del tiemp
o 
128
 Younossi 1997  
Revisado el 28 de diciembre de 1998  3 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas veces  
6 Casi nunca  
7 Nunca  
 
 
 
20. D
urante las últi
mas do
s semanas ¿con qué frecuencia no ha podido quedarse dormido por 
la noche?  
 1 Siempre  
2 La mayor parte
 del tiemp
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 21. D
urante las últi
mas do
s semanas ¿con qué frecuencia ha sufrido calambres musculares?  
 
1 Siempre  
2 La mayor parte 
del tiemp
o 
3
 Una buena parte del t iempo 
4 Algunas veces  
5 Muy 
pocas veces  
6 Casi nunca  
7 Nunca  
 
22. 
 Durante las úl
timas 
dos semanas ¿con qué frecuencia ha estado preocupado por la 
posibilidad de que sus síntomas se
 conviertan en problemas más graves?  
 1 Siempre  
2 La mayor parte del tiemp 
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 
23. D
urante las últi
mas do
s semanas ¿con qué frecuencia ha tenido la boca reseca?  
 
1 Siempre  
2 La mayor parte 
del tiemp
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas veces  
6 C
asi nunca  
7 Nunca  
 
24. Durant
e las 
últimas do
s semanas ¿con qué frecuencia se ha sentido deprimido?  
 
1 Siempre  
2 La mayor parte 
del tiemp
o 
129
 Younossi 1997  
Revisado el 28 de diciembre de 1998  3 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas veces  
6 Casi nunca  
7 Nunca  
 
 
 
25. D
urante l as últim
as dos 
semanas ¿con qué fr ecuencia ha estado preocupado por la 
posibilidad de que su enfermedad empeore?  
 1 Siempre  
2 La mayor parte del tiemp 
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 26. D
urante las últ im
as dos 
semanas ¿con qué frecuencia ha  tenido dificultad para 
concentrarse?  
 1 Siempre  
2 La mayor parte del tiemp 
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 27. D
urante las últi
mas do
s semanas ¿con qué frecuencia ha sufrido molestias a causa de 
pi[INVESTIGATOR_21695]ó
n? 
 1 Siempre  
2 La mayor parte del tiemp 
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 28. D
urante las últi
mas do
s semanas ¿con qué frecuencia ha estado preocupado por la 
posibi lidad de que usted nunca se sienta 
mejor? 
 1 Siempre  
2 La mayor parte del tiemp 
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
 
29. D
urante las últi
mas do
s semanas ¿con qué frecuencia ha estado preocupado por la 
disponibilidad de un hígado si ust
ed llegara a necesitar un trasplante? 
130
 Younossi 1997  
Revisado el 28 de diciembre de 1998   
1 Siempre  
2 La mayor parte del tiemp
o 
3
 Una buena parte del tiempo  
4 Algunas veces  
5 Muy pocas vece
s 
6 Casi nunca  
7 Nunca  
131
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 110 12.4 Alcohol TLFB  
Sobell LC, Maisto SA, Sobell MB, et al. Relia bility of alcohol abusers’ self-reports of 
drinking behavior. Behav Res Ther. 1979;17(2):157-60. 
Sobell LC, Sobell MB. Timeline Follow-back: A technique for assessing self-reported 
alcohol consumption. In: Litten RZ, Allen JP (editors). Measuring alcohol consumption: 
Psychosocial and biochemical methods . Humana; -Totowa, NJ: 1992. P. 41-72. 
Sobell LC and Sobell MB. Alcohol Timeline Fo llowback (TLFB) Users’ Manual. Toronto: 
Addiction Research Foundation, 1995. 
12.4.1  Alcohol TLFB Calendar 2015 
132
Name/ID#:    Date:   
 
TIMELINE FOLLOWBACK CALENDAR: 2015 
 
 
    
 
    
 
 
2015  SUN MON TUES WED THURS FRI SAT 
     1 New Year’s Day 2 3 
J 4 5 6 7 8 9 10 
A 11 12 13 14 15 16 17 
N 18 19 M. Luther King  20 21 22 23 24 
 25 26 27 28 29 30 31 
F 1 2 3 4 5 6 7 
E 8 9 10 11 12 13 14 Valentine’s Day 
B [ADDRESS_20716]. Patrick’s Day 18 19 20 21 
 22 23 24 25 26 27 28 
 29 30 31 1 2 3 Passover 4 Good Friday 
A 5 Easter 6 7 8 9  10   11  
P 12  13  14 15 16 17 18 
R 19 20  21 22 23 24 25 
 26 27 28 29 30 1 2 
M 3 4 5 6 7 8 9 
A 10 Mother’s Day 11 12 13 14 15 16 
Y 17 18 19 20 21 22 23 
 24 25 Memorial Day  26 27 28 29 30 
 31       
 One 5 oz glass of 
regular (12%) 
wine [ADDRESS_20717] liquor 
(e.g. rum, vodka, 
whiskey) [ADDRESS_20718] Drink is Equal to 
One 12 oz can/bottle of 
beer 
Complete the Following 
Start Date  (Day 1):         End Date (yesterday):     
MO  DY        YR     MO  DY        YR  
133
TLFB 2015 
  2 
 
TLFB 2004 2  
2015  SUN MON TUES WED THURS FRI SAT 
  1 2 3 4 5 6 
J 7 8 9 10 11 12 13 
U 14 15 16 17 18 19 20 
N 21 Father’s Day 22 23 24 25 26 27 
 28 29 30 1   2 3 4 Independence Day  
J 5 6 7 8 9 10 11 
U 12 13 14 15 16 17 18 
L 19 20  21 22 23 24 25 
 26 27 28 29 30 31 1 
A 2 3   4 5 6 7 8 
U 9 10 11 12 13 14 15 
G 16 17 18 19 20 21 22 
 23 24 25 26 27 28 29 
 30 31 1 2 3 4 5 
S 6 7 Labor Day 8 9 10 11 12 
E 13 Rosh Hashanah 14 15 16 17 18 19 Rosh Hashanah 
P 20 21  22 Yom Kippur 23 24 25 26 
 27 28  29 30  1 2 3 
O 4 5 6 7 8 9 10 
C 11 12 Columbus Day 13 14 15 16 17 
T 18 19 20 21 22 23 24 
 25 26 27 28 29 30 31 Halloween 
N 1 2 3 Election Day  4 5 6 7 
O 8 9 10  11 Veterans Day 12 13 14 
V 15 16 17 18 19 20 21 
 22 23 24 25 26 Thanksgiving  27 28 
 29 30 1 2 3 4 5 
D 6 Hanukkah 7 8 9 10 11 12  
E 13 14  15 16 17 18 19 
C 20 21 22 23 24 25 Christmas  26   
 27 28 29 30 31 New Year’s Eve    
134
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 111 12.4.2  Alcohol TLFB Calendar 2016 
135
Name/ID#:    Date:   
 
TIMELINE FOLLOWBACK CALENDAR: 2016 
 
 
    
 
    
 
2016  SUN MON TUES WED THURS FRI SAT 
      1 New Year’s  2 
J 3 4 5 6 7 8 Chinese New Yr 9 
A 10 11 12 13 14 15 16 
N 17 18  M. Luther King  19 20 21 22 23 
 24 25 26 27 28 29 30 
 31 1 2 3 4 5 6 
F 7 8 9 10 11 12 13 
E 14 Valentine’s Day 15 President’s Day  [ADDRESS_20719].Patrick’s Day 18 19 
R 20 21 22 23 24 25 Good Friday 26 
 27 Easter Sunday 28 29 39 31 1 2 
A 3 4 5 6 7 8 9 
P 10 11 12 13 14 15 15 
R 17 18 19 20 21 22 Passover 23 
 24 25 26 27 28 29 30 
M 1 2 3 4 5 6 7 
A 8 Mother’s Day 9 10 11 12 13 14 
Y 15 16 17 18 19 20 21 
 22 23  24 25 26 27 28 
 29 30 Memorial Day 31     
 One 5 oz glass of 
regular (12%) 
wine [ADDRESS_20720] liquor 
(e.g. rum, vodka, 
whiskey) [ADDRESS_20721] Drink is Equal to 
One 12 oz can/bottle of 
beer 
Complete the Following 
Start Date  (Day 1):         End Date (yesterday):     
MO  DY        YR     MO  DY        YR  
136
TLFB 2016  2  
 
    
 2  
2016  SUN MON TUES WED THURS FRI SAT 
    1 2 3 4 
J 5 6 7 8 9 10 11 
U 12 13 14 15 16 17 18 
N 19Father’s Day 20 21 22 23 24 25 
26 26 27 28 29 30 1 2 
J 3  4 Independence Day 5 6 7 8 19 
U 10 11 12 13 14 15 16 
L 17 18 19 20 21 22 23 
 24 25 26 27 28 29 30 
A 31 1 2 3 4 5 6 
U 7 8 9 10 11 12 13 
G 14 15 16 17 18 19 20 
 21 22 23 24 25 26 27 
 28 29 30 31 1 2 3 
S 4 5 6 7 8 9 10 
E 11 12 13 14 15 16 17 
P 18 19 20 21 22 23 24 
 25 26 27 28 29 30 1 
O 2 Rosh Hashanah 3 4 5 6 7 8 
C 9 10 11 12 Yom Kippur 13 14 15 
T 16 17 18 19 20 21 22 
 23 24 25 26 27 28 29 
 30 31 Halloween 1 2 3 4 5 
N 6 7 8 Election Day 9 10  11 Veterans’ Day 12 
O 13 14 Columbus Day 15 16 17 18 19 
V 20 21 22 23 24 Thanksgiving 25 26 
 27 28 29 30 1 2 3 
D 4 5 6 7 8 9 10 
E 11 12 13 14 15 16 17 
C 18 19 20 21 22 23  24 Hanukkah 
 25 Christmas 26 27 28 29 30 31 New Year’s Eve 
  
137
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 112 12.4.3  Alcohol TLFB Calendar 2017 
138
Name/ID#:    Date:   
 
TIMELINE FOLLOWBACK CALENDAR: 2017 
 
   
 
     
 
  
 
 
 
2017  SUN MON TUES WED THURS FRI SAT 
 1 New Year’s 2 3 4 5 6 7 
J 8 9 10 11 12 13 14 
A 15 16 M. L. King  17 18 19 20 21 
N 22 23 24 25 26 27 28Chinese New Yr 
 29 30 31 1 2 3 4 
F 5 6 7 8 9 1 0 11 
E 12 13 14 Valentine’s Day   15 16 17 18 
B 19 20 Presidents’ Day [ADDRESS_20722]. Patrick’s Day  18  
R 19 20 21 22 23 24 25 
 26 27 28 29 30 31 1 
A 2 3 4  5 6 7   8 
P 9  10 11 Passover 12 13  14 Good Friday 15 
R 16  Easter 17 18 19 20 21 22 
 23 24 25 26 27 28 29 
 30 1 2 3 4 5 6 
M 7 8 9 10 11 12 13 
A 14 Mother’s Day 15 16 17 18 19 20 
Y 21 22 23 24 25 26 27 
 28 29 Memorial Day 30 31    
 
 
 
 One 5 oz glass of 
regular (12%) 
wine [ADDRESS_20723] liquor 
(e.g. rum, vodka, 
whiskey) [ADDRESS_20724] Drink is Equal to 
One 12 oz 
can/bottle 
of beer 
Complete the Following 
Start Date  (Day 1):         End Date (yesterday):     
MO  DY        YR     MO DY YR  
139
TLFB 2017   2 
 
  
2017  SUN MON TUES WED THURS FRI SAT 
     1 2 3 
J 4 5 6 7 8 9 1 0 
U 11 12 13 14 15 16 17 
N 18 Father’s Day 19 20 21 22 23 24 
 25 26 27 28 29 30 1 
J 2 3 4  July 4th 5 6 7 8 
U 9 10 11 12 13 14 15 
L 16 17 18 19 20 21 22 
 23 24 25 26 27 28 29 
 30 31 1 2 3 4 5 
A 6 7 8 9 1 0 11 12 
U 13 14 15 16 17 18 19 
G 20 21 22 23 24 25 26 
 27 28 29 30 31 1 2 
S 3 4 Labor Day 5 6 7 8 9 
E 10 11 12 13 14 15 16 
P 17 18 19 20 21 22 23  
 24 25 26 27 28 29 30 Rosh Hashanah 
O 1 2  3 4 5 6 7 
C 8 9 Columbus Day 10 11 12 13 14 
T 15 16 17 18 19 20 21 
 22 23 24 25 26 27 28 
 29 30 Yom Kippur 31 Halloween 1  2 3 4 
N 5 6 7 8 9 1 0  11 Veterans Day 
O 12  13 14 15 16 17 18 
V 19 20 21 22 23Thanksgiving 24 25 
 26 27 28 29 30 1 2 
D 3 4 5 6   7 8 9 
E 10 11 12 Hanukkah 13 14 15 16  
C 17 18 19 20 21 22 23 
 24 25 Christmas 26  27 28 29 30 
 31 New Years Eve       
 
140
Galectin Therapeutics Inc. GR-MD-02 (galactoarabino-rhamnogalacturnate) 
Protocol: GT-026 Original 20 February 2015 
 Page 113 12.4.4  Instructions for Comple ting the Alcohol TLFB 
141
Sobell, L. C. & Sobell, M. B., [ADDRESS_20725] 
____ days. To do this, we would like you to fill out the attached calendar.  
 Filling ou t the calendar is not hard!  
 Try to be as accurate as possible.  
 We recognize you won’t have perfect recall. That’s OKAY.  
 
 WHAT TO FILL IN 
• The idea is to put a number in for each day on the calendar.  
• On days when you did not drink, you should write a ”0” . 
• On days when you did drink, you should write in the total number of drinks you had.  
• We want you to record your drinking on the calendar using Standard Drinks. For example,  if you had 6 
beers, write the number 6 for that day. If you drank two or more different kinds of alcoholic beverages in a 
day such as 2 beers and 3 glasses of wine, you would write the number 5 for that day.  
It’s important that something is written for every day, even if it is a “0”.  
 
 YOUR BEST ESTIMATE   
• We realize it isn’t easy to recall things with 100% accuracy.  
• If you are not sure whether you drank [ADDRESS_20726] guess!  What is important is that 7 or 11 drinks is very different from 1 or 2 drinks or 25 drinks. The 
goal is to get a sense of how frequently you drank, how much you drank, and your patterns of drinking.  
 
 HELPFUL HINTS  
• If you have an appointment book you can use it to help you recall your drinking.  
• Holidays such as Thanksgiving and Christmas are marked on the calendar to help you better recall your 
drinking. Also, think about how much you drank on personal holidays & events such as birthdays, 
vacations, or parties.  
• If you have regular drinking patterns you can use these to help you recall your drinking. For example, you 
may have a daily or weekend/weekday pattern, or drink more in the summer or on trips, or you may drink 
on Wednesdays after playing sports.  
 
 COMPLETING THE CALENDAR  
• A blank calendar is attached.  Write in the number of Standard Drinks that you had each day .  
• The time period we are talking about on the calendar is  
from ________________________ to _______________________. 
• In estimating your drinking, be as accurate as possible.  
• DOUBLE CHECK THAT ALL DAYS ARE FILLED IN BEFORE RETURNING THE CALENDAR.  
• Before you start look at the SAMPLE CALENDAR AND STANDARD DRINK CHART  on the next page.
142
  2   
 
Sobell, L. C. & Sobell, M. B., 2000   
 Instructions for Filling Out the Timeline Alcohol Use Calendar  
 
 SAMPLE CALENDAR  
 
 
[ADDRESS_20727] Drink Is Equal To  
 
 12 oz of BEER (5%)   
  5 oz of WINE  (10% – 12%)    
  3 oz of FOR
TIFIED WINE (16% – 18%)  
  1.[ADDRESS_20728] LI
QUOR (86 proof – 100 proof; 43% – 50%)   
  WIN
E: 1 Bottle  
 25 oz/750 ml  = [ADDRESS_20729] drinks  
 40 oz/1.5 
liter = [ADDRESS_20730] drinks  
 25 oz for
tified = 8 1/[ADDRESS_20731] drinks  
  HARD L
IQUOR: 1 Bottle  
 12 oz (mickey)  = [ADDRESS_20732] drinks  
 26 oz  = 17 1/[ADDRESS_20733] drinks  
 40 oz  = 26 
2/[ADDRESS_20734] drinks  
 
143